

Auditors' Reports as Required by Office of Management and Budget (OMB) Circular A-133 and *Government Auditing Standards* and Related Information

Year ended June 30, 2014

Auditors' Reports as Required by Office of Management and Budget (OMB) Circular A-133 and *Government Auditing Standards* and Related Information

Year ended June 30, 2014

Table of Contents

	Page
Consolidated Financial Statements and Schedule of Expenditures of Federal Awards	
Independent Auditors' Report	1
Consolidated Financial Statements and Related Notes	3
Supplementary Schedule of Expenditures of Federal Awards and Related Notes	29
Reports on Compliance and Internal Control	
Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	49
Independent Auditors' Reports on Compliance for Each Major Federal Program and on Internal Control Over Compliance	51
Findings and Questioned Costs	
Schedule of Findings and Questioned Costs	53



KPMG LLP Two Financial Center 60 South Street Boston, MA 02111

Independent Auditors' Report

The Board of Trustees Boston University:

Report on the Consolidated Financial Statements

We have audited the accompanying consolidated financial statements of Boston University and its subsidiaries, which comprise the consolidated statement of financial position as of June 30, 2014, the related consolidated statements of activities and cash flows for the year then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the organization's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the organization's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Boston University and its subsidiaries as of June 30, 2014, and the changes in their net assets and their cash flows for the year then ended in accordance with U.S. generally accepted accounting principles.

Other Matters

Predecessor Auditors' Opinion

The accompanying consolidated financial statements of Boston University and its subsidiaries as of June 30, 2013 and for the year then ended were audited by other auditors whose report thereon dated September 19, 2013, expressed an unmodified opinion on those consolidated financial statements.

Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying supplementary schedule of expenditures of federal awards is presented for purposes of additional analysis, as required by Office of Management and Budget Circular A-133, *Audits of States, Local Governments, and Non-Profit Organizations*, and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the supplementary schedule of expenditure of federal awards is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated September 17, 2014 on our consideration of Boston University's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Boston University's internal control over financial reporting and compliance.



September 17, 2014, except as to the supplementary schedule of expenditures of federal awards, which is as of December 10, 2014

BOSTON UNIVERSITY • CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

June 30, 2014 and 2013 (\$000)

	2014	2013
ASSETS		
Cash and cash equivalents	\$ 572,114	\$ 551,775
Cash and cash equivalents-restricted	163,436	184,013
Short-term investments	1,705	1,454
Accounts and loans receivable, net	188,641	186,877
Pledges receivable, net	121,178	124,701
Prepaid expenses and other assets	100,340	97,485
Residual asset note receivable	53,285	53,014
Long-term investments	1,611,101	1,417,331
Property, plant, and equipment, net	2,136,638	2,043,814
Total assets	\$ 4,948,438	\$ 4,660,464
LIABILITIES AND NET ASSETS Liabilities:		
Accrued payroll and related expenses	\$ 108,601	\$ 107,684
Accounts payable and accrued expenses	219,181	219,728
Fair value of interest rate exchange agreements	242,303	227,835
Deferred revenue	80,127	84,202
Student deposits	86,442	83,130
Annuities payable	15,092	16,779
Residual asset note obligation	53,285	53,014
Capital lease obligation	83,714	84,071
Bonds and notes payable, net	 1,328,518	 1,336,388
Total liabilities	 2,217,263	 2,212,831
Net assets:		
Unrestricted	1,538,141	1,388,789
Temporarily restricted	687,765	593,843
Permanently restricted	 505,269	 465,001
Total net assets	 2,731,175	 2,447,633

BOSTON UNIVERSITY • CONSOLIDATED STATEMENTS OF ACTIVITIES

For the years ended June 30, 2014 and 2013 (\$000)

	2014					
ODED ATTING DEVENING	Unrestricted	Temporarily Restricted	Permanently Restricted	Total		
OPERATING REVENUES Student tuition and fees	\$ 1,204,646 (299,838)	\$	\$	\$1,204,646 (299,838)		
Net student tuition and fees	904,808			904,808		
Sponsored programs	236,952 123,547 30,261 108,528			236,952 123,547 30,261 108,528		
Spending formula and other investment income	44,528			44,528		
Sponsored program income for student aid	14,684			14,684		
Auxiliary enterprises	260,992			260,992		
Student aid	(4,420)			(4,420)		
Net auxiliary enterprises	256,572			256,572		
Contributions used for operations	7,728	·		7,728		
Total operating revenues	1,727,608			1,727,608		
OPERATING EXPENSES						
Instruction and departmental research	779,346			779,346		
Educational support activities	118,285			118,285		
Sponsored programs	235,702			235,702		
Libraries	26,716			26,716		
Institutional support	247,356			247,356		
Student support	11,173			11,173		
Auxiliary enterprises	197,402			197,402		
Total operating expenses	1,615,980			1,615,980		
Change in net assets from operating activities	111,628			111,628		
NONOPERATING REVENUES (EXPENSES)						
Contributions		11,591 (7,728)	36,458	48,049 (7,728)		
other investment income	2,236	2,251	651	5,138		
formula amount	64,853	97,158	4,788	166,799		
Net realized and unrealized (losses) gains on interest rate exchange agreements	(39,906)			(39,906)		
institutional real estate	3,976			3,976		
net periodic cost	(2,543)	(0.250)	(4. (20)	(2,543)		
Other additions (deductions) and transfers, net	9,108	(9,350)	(1,629)	(1,871)		
Net nonoperating income	37,724	93,922	40,268	171,914		
Change in net assets	149,352	93,922	40,268	283,542		
Beginning net assets	1,388,789	593,843	465,001	2,447,633		
Ending net assets	\$ 1,538,141	\$ 687,765	\$ 505,269	\$2,731,175		

BOSTON UNIVERSITY • CONSOLIDATED STATEMENTS OF ACTIVITIES

For the years ended June 30, 2014 and 2013 (\$000)

	201	13		
Unrestricted	Temporarily Restricted	Permanently Restricted	Total	ODED ATTING DEVENIUES
\$ 1,161,520 (291,566)	\$	\$	\$1,161,520 (291,566)	OPERATING REVENUES Student tuition and fees Student aid
869,954			869,954	Net student tuition and fees
240,763			240,763	Sponsored programs
123,066			123,066	Recovery of facilities and administrative costs
31,334			31,334	Contributions
95,110			95,110	Sales and services
40,643			40,643	Spending formula and other investment income
15,790			15,790	Sponsored program income for student aid
265,088			265,088	Auxiliary enterprises
(4,426)	-		(4,426)	Student aid
260,662			260,662	Net auxiliary enterprises
6,322			6,322	Contributions used for operations
1,683,644			1,683,644	Total operating revenues
				OPERATING EXPENSES
767,460			767,460	Instruction and departmental research
108,003			108,003	Educational support activities
237,408			237,408	Sponsored programs
27,037			27,037	Libraries
252,305			252,305	Institutional support
12,560			12,560	Student support
211,744			211,744	Auxiliary enterprises
1,616,517			1,616,517	Total operating expenses
67,127			67,127	Change in net assets from operating activities
				NONOPERATING REVENUES (EXPENSES)
	26,408	34,914	61,322	Contributions
	(6,322)	,	(6,322)	Contributions used for operations
	, , , ,		, , , ,	Reinvested endowment and
3,005	1,426	1,454	5,885	other investment income
				Excess of investment return over spending
33,396	52,422	1,081	86,899	formula amount
				Net realized and unrealized (losses) gains on
78,046			78,046	interest rate exchange agreements
				Change in value of designated non-core
				institutional real estate
				Post-retirement related changes other than
2,957	(4.004)	4.20	2,957	net periodic cost
(10,993)	(1,904)	4,206	(8,691)	Other additions (deductions) and transfers, net
106,411	72,030	41,655	220,096	Net nonoperating income
173,538	72,030	41,655	287,223	Change in net assets
1,215,251	521,813	423,346	2,160,410	Beginning net assets
\$ 1,388,789	\$ 593,843	\$ 465,001	\$2,447,633	Ending net assets

BOSTON UNIVERSITY • CONSOLIDATED STATEMENTS OF CASH FLOWS

For the years ended June 30, 2014 and 2013 (\$000)

		2014		2013
CASH FLOWS FROM OPERATING ACTIVITIES:	φ	202.542	¢	207 222
Change in net assets.	\$	283,542	\$	287,223
Adjustments to reconcile change in net assets to net cash provided				
by operating activities: Depreciation		07.490		93,780
-		96,480 (844)		(522)
Amortization		1,316		6,849
Change in value of designated non-core institutional real estate		(3,976)		0,047
Unrealized losses (gains) on interest rate exchange agreements		14,468		(103,437)
Settlements on swap replacement transactions, net		12,145		12,153
Net realized and unrealized gains on investments		(202,351)		(118,551)
Contributions restricted for long-term investment		(24,848)		(115,070)
Gifts of securities and property		(4,131)		(33,574)
Other non-cash adjustments		(4,131)		153
Changes in operating assets and liabilities:				133
Increase in accounts and loans receivable, net		(1,764)		(4,423)
Decrease (increase) in pledges receivable, net		3,523		(1,784)
Decrease (increase) in pregaid expenses and other assets		476		(4,764)
Decrease in accounts payable and accrued expenses		(5,872)		(11,314)
Increase (decrease) in accrued payroll and related expenses		918		(1,565)
(Decrease) increase in deferred revenue		(4,075)		48,852
Increase (decrease) in student deposits		3,312		(1,867)
		168,319		152,139
Net cash provided by operating activities		168,319		132,139
CASH FLOWS FROM INVESTING ACTIVITIES:				
Purchases of investments		(211,057)		(409,503)
Proceeds from sales and maturities of investments		223,887		366,485
Purchases of property and equipment		(188,003)		(128,951)
Proceeds from sales of gifts of securities and property				31,870
Decrease in cash and cash equivalents-restricted		20,577		24,007
Net cash used in investing activities		(154,596)		(116,092)
CASH FLOWS FROM FINANCING ACTIVITIES:				
Proceeds from bonds and notes payable				111,485
Bond discount				(235)
Bond premium				9,487
Payment of bonds, notes and mortgages		(12,763)		(30,475)
Decrease in annuity obligations		(1,687)		(1,070)
Contributions restricted for long-term investment		24,848		15,070
Proceeds from sale of restricted gifts of securities and property		3,607		,
Settlements on swap replacement transactions, net		(12,145)		(12,153)
Net cash provided by financing activities		1,860		92,109
Unrealized loss (gain) on currency exchange		4,756		(1,265)
Net increase in cash and cash equivalents		20,339		126,891
Cash and cash equivalents beginning of year		551,775		424,884
Cash and cash equivalents end of year	\$	572,114	\$	551,775
SUPPLEMENTAL INFORMATION:				
Change in accounts payable for property, plant, and equipment	\$	1,995	\$	2,254
Acquisition of property and equipment through borrowings Interest paid, net of capitalized interest of	\$	623	\$	1,020
\$5,363 in 2014 and \$2,946 in 2013	\$	41,821	\$	39,343
φο,σου III 2017 and φ2,/το III 2013	φ	71,041	Φ	37,373

1. Organization and Summary of Significant Accounting Policies

Organization:

Boston University (the University) is an independent, nonprofit, coeducational, nonsectarian institute of higher education, founded in 1839 and chartered under the laws of the Commonwealth of Massachusetts on May 26, 1869. The University has two principal campuses, its Charles River Campus located in Boston's Back Bay and its Medical Campus located in the South End of Boston, offering students more than 250 areas of study in 16 schools and colleges.

The University is generally exempt from income tax under Section 501(c)(3) of the U.S. Internal Revenue Code, except to the extent the University has unrelated business income. There was no provision for income taxes due on unrelated business income in fiscal years 2014 and 2013. The University has no material uncertain tax positions.

Summary of Significant Accounting Policies:

Basis of Presentation:

The accompanying consolidated financial statements have been prepared on the accrual basis in accordance with U.S. generally accepted accounting principles (GAAP).

The consolidated financial statements include the University and its wholly owned subsidiaries. All significant intercompany transactions and accounts have been eliminated.

Boston Medical Center is the primary teaching affiliate of the Boston University School of Medicine. Boston Medical Center is a separately governed legal entity organized as a 501(c)(3) and is not consolidated in the accompanying consolidated financial statements.

Net Asset Classification:

Net assets, revenues, and realized and unrealized gains and losses are classified based on the existence or absence of donor-imposed restrictions. Accordingly, net assets and changes in net assets are classified as follows:

Unrestricted net assets are free of donor-imposed restrictions. Contributions, endowment income, gains, and investment income that are received and spent or whose restrictions are met in the same reporting period are reported as unrestricted. Unrestricted net assets may be designated by the Board of Trustees for specific purposes, including to function as endowments.

Temporarily restricted net assets include contributions, pledges, and endowment income for which donor-imposed restrictions as to time or purpose have not been met (primarily future capital projects) and pledges receivable for which the ultimate purpose of the proceeds is not permanently restricted. These net assets are released from restrictions when the specified time elapses or actions have been taken to meet the restrictions. The University is subject to the Massachusetts Uniform Prudent Management of Institutional Funds Act of 2009 (UPMIFA), under which donor-restricted endowment funds may be appropriated for expenditure by the Board of Trustees of the University in accordance with the standard of prudence prescribed by UPMIFA. Net assets of such funds in excess of the fair value of the original gift are classified as temporarily restricted until appropriated by the Board and spent in accordance with the standard of prudence imposed by UPMIFA.

Permanently restricted net assets include contributions, pledges, and income required to be permanently retained and primarily consist of the historic dollar value of contributions to donor-restricted endowment funds.

The composition of net assets as of June 30, 2014 and 2013, in thousands of dollars, is as follows:

The composition of net assets as of June 30, 2014 an	14 2010, III III0400	-)14	
	Unrestricted	Temporarily Restricted	Permanently Restricted	Total
Endowment principal: General purpose Scholarships Professorships Awards, prizes, fellowships, and other Research Annuities Total endowment funds	\$ 413,250 70,293 82,515 19,090 12,150 597,298	\$ 150,655 176,498 127,893 47,598 5,382 23,478 531,504	\$ 106,088 145,479 125,205 31,931 9,988 418,691	\$ 669,993 392,270 335,613 98,619 27,520 23,478 1,547,493
Other funds: General and plant funds. Building and gift funds. Pledges. Student loan funds Designated funds Total other funds. Total net assets.	802,595 66,146 25,875 46,227 940,843 \$ 1,538,141	89,921 61,851 1,668 2,821 156,261 \$ 687,765	59,326 27,252 86,578 \$ 505,269	802,595 156,067 121,177 54,795 49,048 1,183,682 \$ 2,731,175
			013	
	Unrestricted	Temporarily Restricted	Permanently Restricted	Total
Endowment principal: General purpose Scholarships Professorships Awards, prizes, fellowships, and other Research Annuities	Unrestricted \$ 361,577 60,321 64,669 16,813 18,537	Temporarily	Permanently	Total \$ 585,831 339,486 283,172 84,883 29,244 13,045
General purpose	\$ 361,577 60,321 64,669 16,813	Temporarily Restricted \$ 134,736 142,247 101,460 39,136 4,699	Permanently Restricted \$ 89,518 136,918 117,043 28,934	\$ 585,831 339,486 283,172 84,883 29,244
General purpose Scholarships Professorships Awards, prizes, fellowships, and other Research Annuities	\$ 361,577 60,321 64,669 16,813 18,537	Temporarily Restricted \$ 134,736 142,247 101,460 39,136 4,699 13,045	Permanently Restricted \$ 89,518 136,918 117,043 28,934 6,008	\$ 585,831 339,486 283,172 84,883 29,244 13,045
General purpose Scholarships Professorships Awards, prizes, fellowships, and other Research Annuities Total endowment funds Other funds: General and plant funds Building and gift funds Pledges Student loan funds	\$ 361,577 60,321 64,669 16,813 18,537 521,917 736,755 61,313	Temporarily Restricted \$ 134,736 142,247 101,460 39,136 4,699 13,045 435,323	Permanently Restricted \$ 89,518 136,918 117,043 28,934 6,008 378,421	\$ 585,831 339,486 283,172 84,883 29,244 13,045 1,335,661 736,755 153,822 124,701 54,033

Collections:

The University's collections, which were acquired through purchases and contributions since the University's inception, are not recognized as assets on the Consolidated Statements of Financial Position. Purchases of collection items are recorded as decreases in unrestricted net assets in the year in which the items are acquired. Proceeds from dispositions or insurance recoveries are reflected as increases in the appropriate net asset classes.

The University's collections are made up of artifacts of historical significance, scientific specimens, and art objects that are held for educational, research, scientific, and curatorial purposes. Each of the items is cataloged, preserved, and cared for, and activities verifying their existence and assessing their condition are performed regularly. The collections are subject to a policy that requires proceeds from dispositions to be used to acquire other items for collections.

Use of Estimates:

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results may differ from those estimates.

Related Party Transactions:

Under the University's conflict of interest policy, all business and financial relationships among the University and entities affiliated with Trustees or Officers of the University are subject to the review and approval of the Audit Committee of the Board of Trustees.

Cash and Cash Equivalents:

Cash equivalents include certain assets invested in the short-term pool, all of which can be liquidated within thirty (30) days. The University utilizes the short-term pool to fund daily cash needs, and such assets, reported at fair value, primarily consist of short-term U.S. Treasury securities and other short-term highly-liquid investments.

Cash and cash equivalents-restricted represent funds (a) held by bond trustees that will be drawn down to fund various capital projects and costs of issuance and (b) collateral posted with counterparties under the terms of certain derivative agreements.

Fair Value Measurements:

Investments and interest rate exchange agreements are reported at fair value in the University's consolidated financial statements. Fair value represents the price that would be received upon the sale of an asset or paid upon the transfer of a liability in an orderly transaction between market participants as of the measurement date. GAAP establishes a fair value hierarchy that prioritizes inputs used to measure fair value into three levels:

- Level 1—quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities.
- Level 2—observable prices that are based on inputs not quoted in active markets, but corroborated by market data. In addition, Level 2 includes investments reported using net asset value (NAV) as a practical expedient to estimate fair value that are redeemable in the near term (generally within one year).
- Level 3—unobservable inputs that are used when little or no market data is available. In addition, Level 3 includes investments reported at NAV that are not redeemable in the near term.

The fair value hierarchy gives the highest priority to Level 1 inputs and the lowest priority to Level 3 inputs. In determining fair value, the University utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.

The majority of the University's investments are held through limited partnerships and commingled funds for which fair value is estimated using NAVs reported by fund managers as a practical expedient. For such investments, GAAP requires that classification within the fair value hierarchy be based on the University's ability to timely redeem its interest rather than on inputs used.

The NAVs or their equivalents, as estimated and reported by the general partners or investment managers, are reviewed and evaluated by the University's Investment Office, in accordance with valuation procedures established by the University's Investment Committee, the Chief Investment Officer, and the Senior Vice President, CFO, and Treasurer.

For the years ended June 30, 2014 and 2013

Valuation results, changes in valuation policies and procedures, and issues regarding valuation that may arise from time to time are reviewed with the University Investment Committee, the Chief Investment Officer, and the Senior Vice President, CFO, and Treasurer.

Non-core institutional real estate is valued using one or more of the following valuation techniques: the use of prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities; or an income approach determining valuation by direct capitalization of net income or discounting future cash flows. Inputs such as capitalization rates, price information, operating statistics, specific and broad credit data, recent transactions, discount rates, and other factors are used in the valuation calculations.

The University discloses fair value information for financial assets and liabilities for which it is practicable to estimate fair value. Financial assets and liabilities not reported at fair value are generally carried at net realizable value, which approximates fair value. Such financial assets and liabilities include cash and equivalents, receivables, accounts payable, and accrued liabilities.

Investments in Perpetual Trusts Held by Others and Split-Interest Agreements:

The University is the beneficiary of certain perpetual trusts held and administered by outside trustees. The University's interests are reported at estimated fair value, based on the value of the underlying assets which approximates the present value of future income from these trusts. These assets fall within Level 3 of the hierarchy. Income distributions from these trusts are recorded as investment income for current operations.

The University's split-interest agreements with donors consist of irrevocable charitable gift annuities and charitable remainder trusts held and administered by others. For annuity contracts, the contributed assets are included in investments at fair value. Contribution revenue, net of the accompanying obligation, is recognized as of the date the donated assets are transferred to the University, and liabilities are recorded at the present value of estimated future payments to the donors and beneficiaries under these agreements. The liabilities are adjusted during the term of the annuities to reflect actuarial gains and losses.

The present values of the estimated future cash receipts from charitable remainder trusts are recognized as assets and contribution revenues as of the dates the trusts are established. Distributions from these trusts are recorded as contributions, and the carrying value of the assets is adjusted for changes in the estimates of future receipts.

Property, Plant, and Equipment:

Land, buildings, equipment, and library books are reported at cost or estimated fair value at the date of contribution. Maintenance and repairs are expensed as incurred and improvements that increase the useful life of the asset are capitalized. Costs associated with the construction of new facilities are reported as additions to construction in progress when expended until such projects are completed. Equipment includes general and scientific equipment, computers, furniture, and vehicles.

The University acquired equipment or other assets of approximately \$2,990,000 in 2014 and \$4,057,000 in 2013 through the use of federal funds. In most cases, the University continues to maintain the assets after the granting agreement expires.

Depreciation is computed on a straight-line basis over the remaining useful lives of assets as follows: buildings, 50 years; renovations and improvements, 20 years or lease term, if shorter; University buildings used in sponsored research activities, 12 to 50 years, by using the distinct useful lives for each major building component; equipment, 2 to 20 years; internally used software, 20 years; and library books, 10 years. Depreciation expense for the years ended June 30, 2014 and 2013 was \$96,480,000 and \$93,780,000, respectively.

Long-lived assets and certain intangibles are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. When such events or changes in circumstances indicate an asset may not be recoverable, an impairment loss is recognized in an amount by which the asset's net carrying value exceeds its estimated fair value.

Conditional Asset Retirement Obligations:

The University recognizes the fair value of a liability for legal obligations associated with asset retirements in the period in which the obligation is incurred. When the liability is initially recorded, the cost of the asset retirement obligation is capi-

talized by increasing the carrying amount of the related long-lived asset. The liability is accreted to its present value each period, and the capitalized cost associated with the retirement obligation is depreciated over the useful life of the related asset. Upon settlement of the obligation, any difference between the cost to settle the asset retirement obligation and the liability recorded is recognized as a gain or loss in the Consolidated Statements of Activities.

The asset retirement obligation at June 30, 2014 and 2013, was \$15,090,000 and \$13,704,000, respectively, and is included in accounts payable and accrued expenses in the Consolidated Statements of Financial Position.

Tuition and Fees:

Student tuition and fees are reported as revenue in the year the related academic services are rendered. Student tuition and fees received in advance of services to be rendered are reported as student deposits.

Student Aid:

Student aid in the amount of \$299,838,000 and \$291,566,000 for the years ended June 30, 2014 and 2013, respectively, has been classified as a reduction of student tuition and fees. In addition, student aid in the amount of \$4,420,000 and \$4,426,000 for the years ended June 30, 2014 and 2013, respectively, has been presented as a reduction of auxiliary enterprises (room and board) revenue.

In addition to tuition, fees, room and board, student support in the amount of \$11,173,000 and \$12,560,000 for the years ended June 30, 2014 and 2013, respectively, has been presented as an operating expense.

Sponsored Programs:

Revenues associated with contracts and grants are recognized as the related expenses or capital expenditures are incurred. Grant revenue used for the construction or acquisition of plant is reported within nonoperating activities. The University recognized reimbursement of facilities and administrative costs relating to government contracts and grants at authorized rates each year. All funds expended in connection with government grants and contracts are subject to audit by granting agencies. In the opinion of management, any potential liability resulting from these audits will not have a material effect on the University's financial position.

Contributions:

Contributions, including unconditional promises to give, are recognized upon receipt. Contributions other than cash are recorded at fair value at the date of contribution. Contributions with donor-imposed restrictions, which are reported as temporarily restricted revenues, are reclassified to unrestricted net assets when an expenditure is incurred that satisfies the restriction. Pledges receivable are carried at estimated net present value, net of allowance for uncollectible amounts. Conditional promises to give are not recognized until the conditions on which they depend are substantially met.

Allocation of Expenses:

Certain indirect costs have been allocated to functional expenses in the Consolidated Statements of Activities. These expenses are comprised of, in thousands of dollars:

	 2014			2013
Operation and maintenance of plant	\$ 106,872	9	5	108,631
Interest on indebtedness	42,155			40,407
Depreciation	96,480			93,780

Nonoperating Activities:

Nonoperating activities reflect transactions of a long-term investment or capital nature, including contributions to be received in the future, gains and losses on interest rate exchange agreements, the excess of investment returns over the spending formula amount, post-retirement benefit related changes other than net periodic cost, and certain other nonrecurring activities.

Reclassifications:

Certain 2013 balances previously reported have been reclassified to conform to the 2014 presentation. These reclassifications are not considered material.

During 2014, the University determined that certain obligations and deferred revenue amounts, totaling \$8,000,000 as of June 30, 2012 and \$46,367,000 as of June 30, 2013, that had been previously associated with the University's endowments, are more appropriately classified as offsets to the University's general and plant funds.

Effective in fiscal 2014, the University adopted Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) No. 2012-05, Classification of the Sale Proceeds of Donated Financial Assets in the Statement of Cash Flows, which is effective for fiscal years beginning after June 15, 2013. This standard clarifies that donated securities that are nearly immediately converted to cash and are not restricted for long-term purposes should be presented as cash flows from operating activities in the statement of cash flows.

2. Investments

Basis of Reporting:

Investments consist of directly held equity and fixed income securities, registered mutual funds, exchange traded funds, commingled funds, limited partnerships, non-core institutional real estate, and split-interest agreements. Investments are reported at estimated fair value.

If an investment is held directly by the University and an active market with quoted prices exists, the market price of an identical security is used as reported fair value. The majority of the University's investments are in shares or units of institutional commingled funds and limited partnerships invested in equity, fixed income, hedge, natural resources, private equity, or real estate strategies. Hedge strategies involve funds whose managers have the authority to invest in various asset classes at their discretion, including the ability to invest long and short. Funds with hedge strategies generally hold securities or other financial instruments for which a ready market exists and may include stocks, bonds, put or call options, swaps, currency hedges and other instruments, which are valued by the investment manager accordingly. Private equity funds employ buyout, growth and venture capital, and distressed security strategies. Real estate and natural resources funds generally hold interests in private real estate, oil and gas partnerships and mineral holdings.

The University's interests in commingled investment funds are generally reported at the NAV reported by the fund managers and assessed as reasonable by the University. NAV is used as a practical expedient to estimate the fair value of the University's interest therein, unless it is probable that all or a portion of the investment will be sold for an amount different from NAV. As of June 30, 2014 and 2013, the University had no plans or intentions to sell investments at amounts different from NAV.

Although the University's alternative fund managers adhere to fair value accounting as required by ASC 820, *Fair Value Measurements and Disclosures*, because of inherent uncertainties in valuation assumptions, the estimated fair values for alternative investments such as private equity and private real estate may differ significantly from values that would have been used had a ready market existed, and the differences could be material. Such valuations are determined by fund managers and generally consider variables such as operating results, comparable earnings multiples, projected cash flows, recent sales prices, and other pertinent information.

The fair value of non-core institutional real estate is based on independent appraisals and broker opinions of value, including recent sales of similar properties in the same region and in an active market. The determination of whether a real estate market is active is based on the median number of days to sale for properties with a similar geographic location, type, size, condition, and long-term occupancy rate. When independent appraisals have not been carried out and where comparable sales information is not available, a direct capitalization model is used, with significant assumptions including rental rates ranging from \$11 to \$35 per square foot, vacancy rates of between zero and 20%, and capitalization rates of between 6% and 13%. Significant changes in these inputs in isolation may result in a significantly lower or higher fair value measure.

For the years ended June 30, 2014 and 2013

Cash and investments included in the Consolidated Statements of Financial Position at June 30, 2014 and 2013 were as follows, in thousands of dollars:

	2014	2013
Cash and cash equivalents	\$ 572,114	\$ 551,775
Cash and cash equivalents-restricted	163,436	184,013
Short-term investments	1,705	1,454
Residual asset note receivable	53,285	53,014
Long-term investments	1,611,101	_1,417,331
	2,401,641	2,207,587
Less assets not at fair value:		
Residual asset note receivable	(53,285)	(53,014)
Real estate partnerships accounted for under the		
equity method	(27,738)	(25,518)
Cash and investments at fair value	\$2,320,618	\$2,129,055

The following tables summarize in the fair value hierarchy the University's cash and investments as of June 30, 2014 and 2013, in thousands of dollars:

As of June 30, 2014	Level 1	<u>. </u>	Level 2	Level 3	F	Total Fair Value
Cash and cash equivalents	\$ 735,5	550	\$	\$	\$	735,550
Common and preferred equities:	04.6	.0.2	0 < < 0.5			477.760
Domestic	81,0		96,685			177,768
International	154,5	556	132,424	1,07	<u> </u>	288,057
	235,6	39	229,109	1,07	7	465,825
Fixed Income:						
Domestic	1,7	795	258) }		2,053
International	2	204				204
US government and agencies	92,3	<u> 79</u>			_	92,379
	94,3	378	258			94,636
Alternatives:						
Hedge			408,707	84,803	3	493,510
Natural resources				35,113	3	35,113
Private				190,253		190,253
Real estate				300,848		300,848
			408,707	611,01	7	1,019,724
Split-interest agreements held				-		
by third parties				4,883	3	4,883
Total	\$ 1,065,5	67	\$ 638,074	\$ 616,97	<u>\$</u>	2,320,618

As of June 30, 2013	Level 1	Level 2	Level 3	Total Fair Value
Cash and cash equivalents	\$ 735,788	\$	\$	\$ 735,788
Common and preferred equities:	-2.2 02	-40-0		10=016
Domestic	72,293	54,953		127,246
International	44,965	146,714	1,099	192,778
	117,258	201,667	1,099	320,024
Fixed Income:				
Domestic	2,508	246		2,754
International	356			356
US government and agencies	99,751			99,751
	102,615	246		102,861
Alternatives:				
Hedge		365,606	72,718	438,324
Natural resources	1,508	13,982	25,899	41,389
Private			192,609	192,609
Real estate		130,209	163,274	293,483
	1,508	509,797	454,500	965,805
Split-interest agreements held				
by third parties			4,577	4,577
Total	\$ 957,169	\$ 711,710	\$ 460,176	\$ 2,129,055

Registered mutual funds and exchange traded funds are classified in Level 1 of the fair value hierarchy, as are most securities custodied in the University's name because their fair values are based on quoted prices for identical securities. Investments classified in Levels 2 and 3 consist primarily of shares or units in funds as opposed to direct interests in the funds' underlying securities, which may be readily marketable and not difficult to value. The majority of these funds' investment managers are now registered as required by the Securities and Exchange Commission or similar international regulatory bodies.

The NAV reported by each fund categorized in Level 2 or 3 of the fair value hierarchy is used as a practical expedient to estimate the fair value of the University's interest therein. Its classification in Level 2 or 3 is based on the University's ability to redeem its interest at or near the date of the Consolidated Statement of Financial Position. If the interest can be redeemed in the near term (generally within one year), the investment is classified in Level 2. Accordingly, the inputs or methodology used for valuing or classifying investments for leveling purposes are not necessarily an indication of the risks associated with those investments or the degree of difficulty in estimating the fair value of each fund's underlying assets and liabilities.

Certain hedge funds contain lockup provisions. Under such provisions, share classes of the investment are available for redemption at various times in accordance with the management agreement with the fund.

For the years ended June 30, 2014 and 2013

The following tables present a summary of the University's activity for the years ended June 30, 2014 and 2013 for investments classified in Level 3, in thousands of dollars:

	Common						
	and Preferred					Split-Interest	
	Equities		Altern	natives		Agreements	
			Natural			Held by	Total Assets
2014	International	Hedge	Resources	Private	Real Estate	Third Parties	at Fair Value
Fair value, July 1, 2013	\$ 1,099	\$ 72,718	\$ 25,899	\$192,609	\$163,274	\$ 4,577	\$460,176
Purchases	1,087	22,000	9,442	22,618	8,285	1,303	64,735
Sales or redemptions	(1,105)	(428)	(1,780)	(54,966)	(13,316)		(71,595)
Realized gains (losses)				25,492	2,835	(3,192)	25,135
Unrealized gains (losses)	(4)	13,767	1,552	4,500	3,650	2,195	25,660
Transfers to Level 3		11,142			136,120		147,262
Transfers from Level 3		(34,396)					(34,396)
Fair value, June 30, 2014	\$ 1,077	\$ 84,803	\$ 35,113	\$190,253	\$300,848	\$ 4,883	\$616,977

	(Common									
	and	l Preferred							Spl	it-Interest	
]	Equities				Alterr	natives		Αg	greements	
						Natural]	Held by	Total Assets
2013	Int	ernational	_	Hedge	_F	Resources	Private	Real Estate	Th	ird Parties	at Fair Value
Fair value, July 1, 2012	\$	1,021	\$	29,646	\$	17,152	\$200,385	\$195,735	\$	4,392	\$448,331
Purchases		792		4,170		7,598	19,921	10,786			43,267
Sales or redemptions		(1,653)		(1,486)		(782)	(53,550)	(41,042)			(98,513)
Realized gains (losses)				94		301	13,029	(3,582)			9,842
Unrealized gains (losses)		38		1,577		1,630	12,824	1,377		185	17,631
Transfers to Level 3		901		46,801							47,702
Transfers from Level 3				(8,084)							(8,084)
Fair value, June 30, 2013	\$	1,099	\$	72,718	\$	25,899	\$192,609	\$163,274	\$	4,577	\$460,176

There have been no significant changes in valuation techniques and related inputs used by the University.

The realized and unrealized gains (losses) in the tables above reflect the excess of investment return over the spending formula amount in the accompanying Consolidated Statements of Activities. Unrealized gains (losses) relate to those investments held by the University at June 30, 2014 and 2013. Transfers from Level 3 to Level 2 relate primarily to the release of lockup features on commingled vehicles having redemption terms that provide for liquidity within the 12 months following the reporting period. The University's policy is to recognize transfers as of the end of the year. Transfers from Level 2 to Level 3 were due to changes in the underlying investments and refinements to the valuation methodology applied.

For the years ended June 30, 2014 and 2013, there were no transfers between Level 1 and Level 2.

For the years ended June 30, 2014 and 2013

Investment Related Derivatives:

The endowment employs certain derivative financial instruments to replicate long asset positions more cost effectively than through purchases or sales of the underlying assets.

As a result of entering investment derivative agreements, the University is subject to market volatility consistent with the underlying asset classes. The University has established policies, procedures, and internal controls governing the use of derivatives.

The purchase and sale of exchange-traded derivatives require collateral deposits with the Futures Commission Merchant (FCM). Collateral is posted and moved on a daily basis as required by the rules of the exchange on which the derivatives are traded. In the event of an FCM's insolvency, recovery may be limited to the University's pro-rata share of segregated customer funds available. It is possible that the recovery amount could be less than the total cash or other collateral posted. The collateral is generally in the form of debt obligations issued by the U.S. Treasury or cash. Cash collateral and certain securities owned by the University were held at counterparty brokers to collateralize these positions and are included in cash and cash equivalents-restricted on the Consolidated Statements of Financial Position. As of June 30, 2014 and 2013, the aggregate notional exposure on long-term assets was \$127,385,000 and \$143,384,000, respectively. The associated unrealized gain (loss) on these assets was \$87,000 and \$(6,563,000), respectively, as of June 30, 2014 and 2013. The notional amount of these derivatives is not recorded on the University's Consolidated Statements of Financial Position.

Residual Asset Note:

In June 2006, the University securitized its interest in an investment banking partnership that owned rights to residual future cash flows. To effect the securitization, the rights to receive the future cash flows were transferred from the University to a 100% owned, bankruptcy remote, special purpose limited liability corporation called BU Funding, LLC (LLC). To finance the transaction, the LLC issued a zero coupon note to Deutsche Bank Litigation Fee Trust (DBLF), collateralized by the LLC's rights to the future cash flow stream. The note had an initial face value of \$88,227,000, the aggregate amount of scheduled cash flows to be received between 2007 and 2021. The purchase price of the note was \$25,244,000 and is non-recourse to the University. As of June 30, 2014 and 2013, the carrying value of the discounted residual asset note receivable and related obligation was \$53,285,000 and \$53,014,000, respectively.

The LLC is consolidated in the financial statements of the University. The LLC's discounted note obligation is recorded as a liability and its investment has been recorded as an asset on the Consolidated Statements of Financial Position. The valuation of this investment was based on a present value analysis using readily available observable market discount factors applied to contractually committed cash inflows and outflows. The discount on the note is amortized over its scheduled maturity using the effective interest method and the note obligation decreases as future residual cash flows are received. As a result, the note and the related asset are expected to decline to a balance of zero in 2021. Upon expected extinguishment of the note in 2021, the University remains the beneficiary of \$39,700,000 of cash flows scheduled for 2022–2025. Consistent with GAAP, due to the uncertainty of the timing and ultimate amount of the additional cash flows, the University recorded a nominal value at inception of the transaction for these future cash flows even though disruption of such cash flows is unlikely.

Real Estate Partnerships:

The University owns shares ranging from 45% to 50% in certain University business-related real estate partnerships with a related party, which have been accounted for using the equity method. The University's ownership interest in these partnerships has been recorded within long-term investments on the Consolidated Statements of Financial Position.

For the years ended June 30, 2014 and 2013

Investment Return:

The following summarizes, in thousands of dollars, the investment return, as reflected in the Consolidated Statements of Activities:

For the year ended June 30, 2014	Unrestricted	Temporarily Restricted	Permanently Restricted	Total
Dividend and interest income Net realized and unrealized gains	\$ 6,993 77,811	\$ 8,127 118,095	\$ 606 4,833	\$ 15,726 200,739
Total return on investments	84,804	126,222	5,439	216,465
Less: Spending formula	(18,262) (1,689)	(29,064)	(651)	(47,977) (1,689)
	(19,951)	(29,064)	(651)	(49,666)
Excess of investment return over spending formula amount	\$ 64,853	\$ 97,158	\$ 4,788	\$ 166,799
For the year ended June 30, 2013	Unrestricted	Temporarily Restricted	Permanently Restricted	Total
For the year ended June 30, 2013 Dividend and interest income Net realized and unrealized gains	Unrestricted \$ 8,302 33,773		•	Total \$ 16,685 116,742
Dividend and interest income	\$ 8,302	Restricted \$ 7,628	Restricted \$ 755	\$ 16,685
Dividend and interest income Net realized and unrealized gains	\$ 8,302 33,773	Restricted \$ 7,628 81,189	Restricted \$ 755 1,780	\$ 16,685 116,742
Dividend and interest income	\$ 8,302 33,773 42,075 (5,933)	Restricted \$ 7,628 81,189 88,817	Restricted \$ 755 1,780 2,535 (1,424)	\$ 16,685 116,742 133,427 (43,752)

Commitments:

Private equity, natural resources, and real estate investments are generally made through private limited partnerships. Under the terms of the partnership agreements, the University makes a commitment of a specific amount of capital to a partnership and is obligated to remit committed funding periodically when capital calls are exercised by the General Partner as the partnership executes on its investment strategy. Private equity, natural resources, and real estate funds are typically structured with investment periods of 3 to 7 years. Subsequent to the expiration of the investment period, a fund is usually prohibited from calling capital for new investments. The aggregate amount of unfunded commitments associated with private limited partnerships as of June 30, 2014 and 2013 was \$145,083,000 and \$108,088,000, respectively. Of this amount, approximately 16% of commitments were for funds whose investment period had expired. The timing and amount of future capital calls expected to be exercised in any particular future year is uncertain.

Liquidity:

Investment liquidity as of June 30, 2014, is aggregated below based on redemption or sale period, in thousands of dollars:

	Daily	Monthly	Quarterly	Annually	>1 Year	Total
Cash and cash equivalents	\$ 735,550	\$	\$	\$	\$	\$ 735,550
Common and preferred equities:						
Domestic	80,922	232	96,614			177,768
International	133,907	105,914	47,159		1,077	288,057
	214,829	106,146	143,773		1,077	465,825
Fixed income:						
Domestic	1,795	258				2,053
International	185	19				204
US government and agencies	92,379					92,379
	94,359	277				94,636
Alternatives:						
Hedge			206,533	202,174	84,803	493,510
Natural resources					35,113	35,113
Private					190,253	190,253
Real estate				219,360	81,488	300,848
			206,533	421,534	391,657	1,019,724
Split-interest agreements held						
by third parties					4,883	4,883
	<u>\$1,044,738</u>	<u>\$ 106,423</u>	\$ 350,306	\$ 421,534	\$ 397,617	\$2,320,618

The University has sole discretion to liquidate its direct holdings in non-core real estate included in the table above under "Annually." These assets are located in the greater Boston market, which is generally active. Notwithstanding that relevant market assumptions have been incorporated where applicable, determining the fair values of such assets involves significant judgment and their ultimate sales price may be materially different than the values reported.

Investments in the ">1 Year" category include non-redeemable assets totaling \$374,084,000, as well as investments with rolling lockup periods totaling \$23,533,000.

3. Endowment Funds

Total endowment assets at June 30, 2014 and 2013 are \$1,616,004,000 and \$1,403,061,000, respectively. A pooled endowment fund is included as part of the University's investments. The amounts distributed from the investment return of pooled investments in any one year may include interest, dividends, and a portion of accumulated investment gains. The distribution amount is established annually and is between 3% and 5% of the market value per share as of the most recent December 31. The actual distribution amount is recommended by management, and approved by the Trustee Executive Committee. If interest, dividends, and gains are not sufficient to support the current year drawdown, the balance is provided from prior year accumulated earnings. Income attributable to shares from newly established endowment funds is reinvested to principal during the initial six months. For the fiscal years ended June 30, 2014 and 2013, the distribution as a percentage of the prior December 31 fair value of the pooled endowment fund was 3.4% and 3.6%, respectively.

At June 30, 2014 and 2013, respectively, approximately \$411,000 and \$1,024,000 of unrealized losses on permanently restricted endowment funds were classified as a reduction in unrestricted net assets as the fair value of these funds was less than their original gift value. Unrestricted net assets will be replenished when the fair value equals or exceeds the original gift value.

For the years ended June 30, 2014 and 2013

The University's endowment includes both donor-restricted endowment funds and funds designated by the Board of Trustees to function as endowments. As required by GAAP, net assets associated with endowment funds, including funds designated by the Board of Trustees to function as endowments, are classified and reported based on the existence or absence of donor-imposed restrictions.

The University classifies as permanently restricted net assets (a) the original value of contributions donated to the permanent endowment, (b) the original value of subsequent contributions to the permanent endowment, and (c) accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund. The remaining portion of the donor-restricted endowment fund that is not classified in permanently restricted net assets is classified as temporarily restricted net assets until those amounts are appropriated for expenditure by the University in a manner consistent with the standard of prudence prescribed by UPMIFA. In accordance with UPMIFA, the University considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds:

- (1) The duration and preservation of the fund
- (2) The purposes of the organization and the donor-restricted endowment fund
- (3) General economic conditions
- (4) The possible effect of inflation and deflation
- (5) The expected total return from income and the appreciation of investments
- (6) Other resources of the organization
- (7) The investment policies of the organization

The University has investment and spending policies for its endowment and similar funds that emphasize long-term capital appreciation as a primary source of return while balancing the dual objectives of growth in capital and principal preservation. Investments are expected to earn inflation-adjusted long-term returns sufficient to maintain or grow the purchasing power of assets, net of spending and investment expenses, within acceptable risk parameters. To satisfy its long-term rate of return objectives, the University relies on a total return strategy in which investment returns are achieved through both capital appreciation and current yield. The University targets a diversified asset allocation of U.S. Treasury bills, common and preferred equities, fixed income, hedge funds, natural resources, private equity, and real estate. The portfolio is expected to produce risk-adjusted returns that exceed the policy benchmarks, a blended rate of indices.

The following table represents endowment net asset composition by type of fund as of June 30, 2014, in thousands of dollars:

	Unrestricted	Temporarily Restricted	Permanently Restricted	Total	
Donor restricted	\$ (411) 597,709	\$ 531,504	\$ 418,691	\$ 949,784 597,709	
Endowment net assets at end of year	\$ 597,298	\$ 531,504	\$ 418,691	\$1,547,493	

For the years ended June 30, 2014 and 2013

The following table represents changes in endowment net assets for the fiscal year ended June 30, 2014, in thousands of dollars:

	Unrestricted	Temporarily Restricted	Permanently Restricted	Total
Endowment net assets at beginning of year Reclassification of net assets	\$ 521,917 613	\$ 435,323 (613)	\$ 378,421	\$1,335,661
Endowment net assets	522,530	434,710	378,421	1,335,661
Reinvested income distribution	2,236	1,295	651	4,182
unrealized gains	61,007	97,142	4,786	162,935
Undistributed investment returns	63,243	98,437	5,437	167,117
Contributions	2,773 8,752	1,636 (3,279)	17,125 17,708	21,534 23,181
Endowment net assets at end of year	\$ 597,298	\$ 531,504	\$ 418,691	\$1,547,493

The following table represents endowment net asset composition by type of fund as of June 30, 2013, in thousands of dollars:

	Unrestricted	Temporarily Restricted	Permanently Restricted	Total
Donor restricted	\$ (1,024)	\$ 435,323	\$ 378,421	\$ 812,720
Board designated	522,941			522,941
Endowment net assets at end of year	\$ 521,917	\$ 435,323	\$ 378,421	\$1,335,661

The following table represents changes in endowment net assets for the fiscal year ended June 30, 2013, in thousands of dollars:

	Unrestricted	Temporarily Restricted	Permanently Restricted	Total
Endowment net assets at beginning of year Reclassification of net assets	\$ 407,322 566	\$ 380,140 (566)	\$ 343,800	\$1,131,262
Endowment net assets	407,888	379,574	343,800	1,131,262
Reinvested income distribution	2,868	1,240	1,424	5,532
and unrealized gains	33,332	52,422	1,075	86,829
Undistributed investment returns	36,200	53,662	2,499	92,361
Contributions	2,655 75,174	1,262 825	12,764 19,358	16,681 95,357
Endowment net assets at end of year	\$ 521,917	\$ 435,323	\$ 378,421	\$1,335,661

4. Accounts Receivable and Pledges Receivable

Accounts Receivable:

Accounts and loans receivable at June 30, 2014 and 2013, in thousands of dollars, consist of the following:

	2014		2013
Accounts receivable, net:			
Students	\$	17,921	\$ 18,092
Less: allowances		(7,292)	 (7,131)
		10,629	 10,961
Grants and contracts		55,388	52,257
Departmental sales, services, and other		55,636	54,895
Less: allowances		(11,184)	 (7,487)
		99,840	 99,665
Student loans		81,484	79,388
Less: allowances		(3,312)	 (3,137)
		78,172	 76,251
Total	\$	188,641	\$ 186,877

Federally sponsored student loans receivable represented \$46,013,000 and \$46,262,000 as of June 30, 2014 and 2013, respectively, of total student loans receivable, which consist of amounts due from current and former students under various federal government loan programs, including Perkins and other health professional programs offered to graduate and undergraduate students. The University has the right to assign loans disbursed under these programs to the federal government upon default by the borrower; therefore, no allowance has been provided for these loans.

The University considered the allowance recorded at June 30, 2014 and 2013 to be reasonable and adequate to absorb potential credit losses inherent in the student loan portfolio.

Departmental sales, services, and other receivables include outstanding notes, mortgages, and advances bearing interest at rates up to 5.21% at June 30, 2014 and 2013, to certain employees. The aggregate amount as of June 30, 2014 and 2013 is \$7,577,000 and \$7,397,000, respectively.

Pledges Receivable:

Pledges consist of unconditional written promises by donors to contribute to the University in the future. At June 30, 2014 and 2013, pledges, in thousands of dollars, are expected to be realized in the following time frame:

	 2014	 2013
In one year or less	\$ 39,606	\$ 34,201
Between one year and five years	91,295	96,821
More than five years	 6,291	 11,663
	137,192	142,685
Discount to present value	(7,714)	(9,684)
Less allowance for unfulfilled pledges	 (8,300)	 (8,300)
Pledges receivable	\$ 121,178	\$ 124,701

5. Property, Plant, and Equipment

Property, plant, and equipment and related accumulated depreciation at June 30, 2014 and 2013, in thousands of dollars, consist of the following:

	 2014	 2013
Land	\$ 100,278	\$ 100,278
Buildings and improvements	2,505,677	2,425,955
Construction in progress	288,347	212,427
Software	54,087	54,087
Equipment	228,817	212,941
Library books	 192,463	 181,795
	3,369,669	3,187,483
Less: accumulated depreciation	 (1,233,031)	 (1,143,669)
Property, plant, and equipment, net	\$ 2,136,638	\$ 2,043,814

As of June 30, 2014 and 2013, buildings and improvements include \$94,293,000 associated with office and research space under capital lease.

Software costs related to Enterprise Resource System implementation projects of \$724,000 were incurred during fiscal year 2013. During 2013, software of \$1,208,000 was placed in service.

As of June 30, 2014 and 2013, capital expenditures of \$199,521,000 were incurred for construction of the National Emerging Infectious Diseases Laboratories (NEIDL). Of this, \$117,796,000 was placed in service during the year ended June 30, 2012. The remaining expenditures are included within construction in progress at June 30, 2014 and 2013, and will be placed in service when the construction is complete and the project is ready for its intended use.

On June 30, 1998, the University entered into an arrangement with a private investor to lease/leaseback four properties with an estimated fair value at that date of approximately \$223,000,000. The lease terms expire between 2039 and 2050, with sublease terms expiring from 2031 through 2040. The University has options to purchase the investor's leasehold interest in the properties at predetermined prices on dates specific to each property from 2015 through 2022. An irrevocable trust sufficient to fund required annual sublease obligations and lease purchase options, all of which the University intends to exercise, was established at the time of the transaction. The transaction did not result in a sale of the properties, which remain on the University's Consolidated Statements of Financial Position and have a net carrying value of \$162,466,000 and \$166,415,000, respectively, as of June 30, 2014 and 2013.

6. Indebtedness

Bonds and Notes Payable:

The principal amounts of bonds and notes payable at June 30, 2014 and 2013, in thousands of dollars, are summarized in the table below. Tax exempt and certain taxable bonds were issued through the Massachusetts Development Finance Agency (MDFA) and the Massachusetts Health and Educational Facilities Authority (HEFA) prior to its merger with MDFA.

	Final	Interest Rate at		Outstandir	ng Pri	ncipal
	Maturity	June 30, 2014		2014		2013
Fixed rate bonds and notes payable:						
MDFA Series P, blended fixed rate	5/15/59	5.63%	\$	100,000	\$	100,000
HEFA Series S, blended fixed rate	10/1/39	4.71%		35,000		35,000
MDFA Series T-1	10/1/39	5.00%		162,740		162,740
MDFA Series T-2 (taxable)	10/1/30	5.27%		4,260		4,260
MDFA Series U-4.	10/1/40	5.65%		50,000		50,000
MDFA Series V-1	10/1/29	5.00%		44,000		44,000
MDFA Series V-2.	10/1/14	2.88%		63,170		63,170
MDFA Series V-3	10/1/14	2.88%		10,200		10,200
MDFA Series W (taxable)	10/1/45	5.20%		100,470		100,470
MDFA Series X, blended fixed rate	10/1/48	4.78%		111,485		111,485
Century notes (taxable)	7/15/97	7.63%		100,000		100,000
Boston Medical Center note (taxable)	5/12/16	2.00%		11,626		17,438
Boston Redevelopment Authority note (taxable)	6/15/21	0.00%		8,015		9,160
Aetna loan (taxable)	9/15/18	10.20%		3,822		4,463
Various notes payable (taxable)	various	various		4,916		5,747
Total fixed rate bonds and notes payable			\$	809,704	\$	818,133
1 ,			<u> </u>			
Variable rate bonds payable:						
HEFA Series H	12/1/29	0.06%	\$	25,000	\$	25,000
HEFA Series N (taxable)	10/1/34	0.11%		30,725		31,020
MDFA Series U-1	10/1/40	0.64%		50,000		50,000
MDFA Series U-2	10/1/40	0.86%		50,000		50,000
MDFA Series U-3	10/1/40	0.04%		50,000		50,000
MDFA Series U-5A	10/1/31	0.03%		36,700		37,600
MDFA Series U-5B	10/1/31	0.07%		38,400		39,300
MDFA Series U-6A	10/1/42	0.66%		62,850		62,850
MDFA Series U-6C	10/1/42	0.03%		52,545		52,545
MDFA Series U-6E	10/1/42	0.61%		62,695		62,695
Royal Bank of Scotland (taxable)	8/15/29	0.97%		41,948		38,807
Total variable rate bonds payable			\$	500,863	\$	499,817
Total bonds and notes payable			<u>\$</u> 1	1,310,567	<u>-</u> \$	1,317,950
Add: Unamortized net premium			Ψ	17,951	Ψ	18,438
Total bonds and notes payable, net			<u></u>	1,328,518	•	1,336,388
Total bonds and notes payable, net			Φ 1	,520,510	Ψ	1,330,300

Certain bond and bank obligations are collateralized by a pledge on tuition revenues, and certain other notes payable are collateralized by plant and property with a net carrying value of \$49,812,000 and \$50,773,000 as of June 30, 2014 and 2013, respectively. The University's bank agreements require annual compliance with financial covenants, including a minimum level of debt service coverage and a minimum level of expendable resources relative to debt. The University was in compliance with financial debt covenants as of June 30, 2014 and 2013.

The fair value of the University's outstanding fixed rate long-term debt was estimated based on recent market data for each debt issue when available. When market data was not available, fair value was estimated based on calculating the present value of the remaining debt service cash flows using a discount rate that takes into consideration comparable terms and estimated yields for similar transactions and obligors. For variable rate debt, the fair value is equal to the carrying value. The inputs to the assumptions used to determine the estimated fair value of debt are based on primarily observable inputs and are classified in Level 2 of the fair value hierarchy. The estimated fair value of the debt portfolio as of June 30, 2014 and June 30, 2013 is \$1,418,963,000 and \$1,372,622,000, respectively.

Scheduled principal payments on bonds and notes payable, in thousands of dollars, are presented in the table below:

	Scheduled			
	Principal			
Year	Maturities			
2015	\$ 86,395			
2016	12,947			
2017	7,760			
2018	8,732			
2019	8,670			
Thereafter	_1,186,063			
Total	\$1,310,567			

Scheduled principal maturities represent aggregate annual payments as required under long-term debt repayment schedules. As of June 30, 2014 and 2013, the University's debt portfolio includes variable rate demand bonds (VRDBs) of \$233,370,000 that are supported by irrevocable letters of credit (LOCs). The LOCs are provided by a diverse group of financial institutions to secure bond repayment and interest obligations and have various maturity dates between July 2015 and June 2018. In the event that a VRDB cannot be remarketed, the bond may be "put" to the LOC provider, resulting in a loan to the University to fund redemption of the bond. If all outstanding VRDBs had been "put" as of June 30, 2014, aggregate scheduled loan repayments under the VRDB-related LOCs would be as follows: \$38,895,000, \$77,790,000, \$77,790,000, and \$38,895,000 in 2015, 2016, 2017, and 2018, respectively. The University has used VRDBs backed by bank LOCs for over 25 years, during which time there have been no instances where a bond failed to be remarketed and was put back to the University.

In April 2013, the University issued its \$111,485,000 Series X tax exempt fixed rate bonds with a final maturity in 2048. The bonds were issued at a premium and generated proceeds of \$120,737,000, which will be used to fund designated capital expenditures and to pay bond issuance costs. Interest is payable at a blended fixed interest rate of 4.78% per annum.

In March 2013, the HEFA Series E Capital Asset Program loan was fully repaid on its scheduled maturity date in the amount of \$18,000,000.

Bank Lines:

The University has \$140,000,000 in committed 364-day lines of credit with five financial institutions. There were no draws or outstanding loans under these lines of credit as of and for the years ended June 30, 2014 and 2013. The current expiration date for all lines of credit is April 2015.

Debt Related Derivatives:

The University has entered into various long-term interest rate exchange agreements to hedge all or a portion of the variable interest rate exposure on certain debt issues, thereby managing the interest cost and risk associated with its outstanding debt. The contracts require the University to make fixed rate interest payments in exchange for variable rate interest payments on the respective notional principal amounts. The variable rate payments received are expected to approximate the interest payable on the underlying variable rate debt. Scheduled reductions of the notional amounts under the swap agreements also generally match the scheduled amortization of the underlying debt.

In connection with its Series V-2 and V-3 fixed rate bonds, the University is also a party to a fixed rate receiver swap. This agreement offsets a portion of the cost of the continuing long-term interest rate exchange agreements associated with refunded bonds.

Below is a summary of the terms of the University's outstanding debt related derivatives as of June 30, 2014 and 2013, in thousands of dollars:

Swap/Swaption	Notional	 Fair '	Valu	ie	Effective	Termination	University	University
Agreement	 Amount	 6/30/14	(6/30/13	Date	Date	Pays	Receives
Series H	\$ 25,000	\$ 8,218	\$	8,279	10/30/1997	12/01/2027	5.28%	SIFMA
Series N	23,485	9,350		9,661	10/30/1997	10/01/2027	6.79%	LIBOR
Series U1–3	150,000	44,968		42,826	10/01/2007	10/01/2040	3.97%*	69% of 1-Mo. USD LIBOR
Series U5	75,100	16,302		16,917	10/30/2001	10/01/2031	4.10%	67% of 1-Mo. USD LIBOR
Series U6	10,700	1,966		2,126	10/01/2002	10/01/2022	4.16%	67% of 1-Mo. USD LIBOR
Series U6, V	239,500	112,079		107,727	7/01/2008	10/01/2042	5.42%*	SIFMA
Series V	73,370	(681)		(1,908)	12/04/2009	10/01/2014	SIFMA	1.94%
Royal Bank of Scotland	41,948	8,697		9,113	8/15/2006	8/15/2029	5.65%	3-Mo. GBP LIBOR +45 basis points
Series S swaption	35,000	10,103		8,189	10/01/2014	on exercise	4.7%**	SIFMA
Series T swaption	162,740	45,463		38,260	10/01/2015	on exercise	4.95%**	SIFMA
Less: Credit valuation								
adjustment		(14,162)		(13,355)				
		\$ 242,303	\$	227,835				

SIFMA—Securities Industry and Financial Markets Association Municipal Swap Index LIBOR—London Interbank Offered Rate

Interest rate exchange liabilities are valued using observable inputs, such as quotations received from the counterparty, dealers, or brokers, whenever available and considered reliable. In instances where models are used to validate extended quotations, the value of the interest rate exchange liability depends upon the contractual terms of, and specific risks inherent in, the instrument as well as the availability and reliability of observable inputs. Such inputs include market prices for reference securities, credit curves, assumptions for nonperformance risk, and correlations of such inputs. The fair value of interest rate exchange agreements is included within Level 2 of the valuation hierarchy.

^{*}Represents a blended interest rate

^{**}If exercised

In 2014 and 2013, the University paid net settlement costs on interest rate exchange agreements of \$25,438,000 and \$25,391,000, respectively. These net settlement costs have been reported in nonoperating activities on the Consolidated Statements of Activities.

For purposes of the Consolidated Statements of Cash Flows, net settlements under the University's interest rate exchange agreements are generally included in cash flows from operating activities. However, in October 2008, the University elected to terminate its existing interest rate exchange agreements with a subsidiary of Lehman Brothers after that firm's bankruptcy and simultaneously entered replacement agreements with new counterparties who provided cash to facilitate settlement of the existing agreements. Accordingly, future net settlements under various replacement agreements, with a total notional amount of \$359,035,000 at June 30, 2014, are considered financing activities. During 2014 and 2013, respectively, net settlement payments of \$12,145,000 and \$12,153,000, were classified as cash flows used in financing activities.

The University's interest rate exchange agreements necessarily involve counterparty credit exposure. The counterparties for the University's agreements are a diversified group of major financial institutions that meet the University's criteria for financial stability and creditworthiness. Interest rate exchange agreements provide for two-way collateral posting requirements intended to mitigate credit risk. At June 30, 2014 and 2013, the University was required to post collateral of \$106,494,000 and \$91,520,000, respectively. Posted collateral balances are included on the consolidated statement of financial position in cash and cash equivalents-restricted. Contractual bilateral collateral posting levels are based on counterparty public debt ratings; current University posting amounts could increase or decrease should the University's credit ratings change. Additionally, interest rate exchange contracts provide for early termination should either counterparty's credit ratings fall below investment grade.

7. Pension and Other Employee Benefits

Defined Contribution Plan:

The University funds retirement plan contributions to Teachers Insurance and Annuity Association–College Retirement Equities Fund (TIAA–CREF), and Fidelity Investments for employees. This 403(b) plan is a defined contribution plan available to all employees who work at least 50% of a full-time schedule, and have an appointment or an expected assignment duration of at least nine months. The expenses for this program amounted to \$63,859,000 in fiscal year 2014 and \$62,103,000 in fiscal year 2013.

Pension and Other Post-Retirement Benefit Plans:

The Boston University Retirement Plan, a qualified defined benefit plan, covered certain University retirees and eligible employees who had elected to participate before December 31, 1986 when the plan was closed to new participants. During 2008, the University initiated the plan termination process. As part of this process, plan assets were used to purchase guaranteed annuities on behalf of the participants to settle the pension liability, and all assets remaining were used to purchase additional benefits for the participants. After receipt of an acceptance of the plan termination filing from the Internal Revenue Service and upon finalization of a plan audit by the Pension Benefit Guarantee Corporation in 2013, the University completed the plan termination process, including the distribution of remaining plan assets to participants and final required filings in 2014.

During fiscal year 2009, the University initiated the process to discontinue a plan option that offers subsidized health care coverage to employees who retire from the University after age 55 until age 65, provided they have at least ten consecutive years of participation in the Plan at the time they retire. Reflecting an extension of the termination date made in fiscal year 2010, the change applied to employees terminating from the University on or after September 1, 2009. The University provides modest life insurance benefits to retirees in the Plan as of January 1, 2007.

In 2013, the University transferred its benefit obligation to provide medical and life insurance benefits for permanently disabled individuals from this plan to its self-insured long term disability plan obligation, included in Accrued Payroll and Related Expenses in the Consolidated Statements of Financial Position. This change resulted in the one-time recognition of net outstanding actuarial losses for these individuals of \$5,500,000. Obligations transferred from the post-retirement obligation to the long-term disability plan obligation totaled \$5,349,000 at July 1, 2012.

Beginning in 2013, the valuation process for the University's post-retirement benefits plan liability was simplified, to reflect actual claims, interest cost, and the amortization of actuarial gains and losses over their expected life. Claims paid, in 2014 and 2013, net of interest cost totaled \$1,000,000 and \$1,100,000 respectively. Actuarial losses and prior service credits previously recognized in the Consolidated Statements of Activities as nonoperating gains and losses are being amortized into operations over time. In 2014 and 2013, this amortization resulted in a net credit to operating expense of \$2,543,000. The University's accrued post-retirement benefit obligation reflected in the Consolidated Statement of Financial Position totaled \$4,900,000 and \$5,900,000 in 2014 and 2013, respectively.

8. Commitments and Contingencies

Leases:

The University is committed to minimum annual rent payments under several long-term non-cancellable operating and capital leases for educational and office space through fiscal year 2033. Amounts scheduled include options to extend capital leases through the year 2066, in thousands of dollars, and are summarized below:

	Operating	_Capital	
2015	\$ 21,964	\$ 3,956	
2016	21,753	4,021	
2017	20,723	4,021	
2018	20,422	4,021	
2019	20,679	4,021	
Thereafter	104,324	188,792	
	\$ 209,865	\$ 208,832	
Less: Amounts			
representing interest		(125,118)	
Capital lease obligation		\$ 83,714	

For 2014 and 2013, rent expense for educational facilities and office space was \$27,807,000 and \$27,859,000, respectively. Certain of these leases provide an option to purchase the properties at fair value.

The University has two leases recorded as capital lease obligations related to a biomedical research facility at 670 Albany Street in Boston. Future minimum lease payments are approximately \$83,714,000 to be paid over the 60-year term of the lease.

Joint Venture Commitments:

The University has entered into certain non-cancellable operating leases expiring through 2030 with its equitymethod real estate partnerships. The partnerships have total assets of \$109,233,000 and \$111,510,000 and total liabilities of \$44,266,000 and \$49,541,000 as of June 30, 2014 and 2013, respectively. The total outstanding debt is equal to \$37,469,000 and \$42,086,000 as of June 30, 2014 and 2013, respectively. The University's share of the debt is \$18,290,000 and \$20,593,000 as of June 30, 2014 and 2013, respectively. The total minimum annual lease payments associated with these leases of approximately \$7,505,000 and \$7,486,000 for the years ended June 30, 2014 and 2013, respectively, are included in the table above.

NEIDL:

In September 2003 the University received an award from the National Institutes of Health (NIH) for the construction of a Biosafety Level (BSL) 4 NEIDL on the University's Medical Campus. The NEIDL is to be used by the University and other organizations to study infectious diseases and to support the federal government's bio-defense effort.

Construction of the NEIDL was substantially completed in 2009. The use of the building for BSL-4 research has been delayed due to pending litigation; with the dismissal of litigation in Massachusetts Superior Court in April 2014, all pending litigation has been resolved, and the University is working to obtain regulatory approval for BSL-4 research from the Boston Public Health Commission. In March of 2012 the University received clearance from the Massachusetts Executive Office of Energy and Environmental Affairs to begin research at NEIDL at Biosafety Level 2 and as of March 15, 2012, the related portion of the facility was placed into service and research began.

The University and Boston Medical Center each committed \$28,300,000 toward construction, and each held a 50% equity interest in the project with the right to share equally in the future operating activities of the NEIDL. In May 2010, in accordance with the terms of the agreement between the University and Boston Medical Center, Boston Medical Center notified the University of its intent to withdraw from further participation in the NEIDL as of May 1, 2011. The agreement required the University to repay Boston Medical Center's equity commitment of \$29,064,000. Repayment terms for this obligation were finalized in February of 2012, with repayment to be made over 5 years at an interest rate of 2%. The balance of this obligation as of June 30, 2014 and 2013, of \$11,626,000 and \$17,438,000, respectively, is reflected in bonds and notes payable.

Total original construction costs were \$199,521,000 as of June 30, 2014 and 2013. NIH has reimbursed \$140,625,000 as of June 30, 2014 and 2013. When initially received by the University, NIH funding for NEIDL construction was recorded as an increase to temporarily restricted net assets, to be released from restriction when the asset is placed in service. As noted above, over 60% of the building was placed into service during 2012, and as a result, in 2012, a prorata share of NIH funding, \$86,507,000, was transferred from temporarily restricted net assets to unrestricted net assets.

Other:

As of June 30, 2014, the University has commitments of approximately \$292,750,000, primarily related to open construction contracts and capital acquisitions. This amount is expected to be financed from operating cash flow, federal government grants, and borrowings.

In December 2012, in connection with the sale of a non-core asset, the University entered into a 75-year ground agreement to lease the land to the purchaser of the building. The lease term is through 2087. In connection with this transaction, the University received a prepaid lease payment of \$38,625,000 that is included in deferred revenue on the Consolidated Statements of Financial Position and will be amortized on a straight-line basis over the term of the lease. For the years ended June 30, 2014 and 2013, the University recognized rental revenue of \$515,000 and \$257,500, respectively, related to the ground lease. The unamortized deferred rent as of June 30, 2014 and 2013 is \$37,853,000 and \$38,368,000, respectively.

Effective July 1, 1996, the University entered into a support agreement with Boston Medical Corporation, which was formed from the merger of Boston City Hospital and Boston Medical Center Hospital. The University's commitment for fiscal year 2014 is approximately \$8,000,000.

The University is a defendant in various legal actions arising in the normal course of its operations. Although the final outcome of such actions cannot currently be determined, the University believes that eventual liability, if any, will not have a material effect on the University's financial position.

9. Subsequent Events

In July 2014, in connection with an existing \$35,000,000 swaption contract related to its Series S bonds, the University was notified of the counterparty's intent to exercise its option effective as of October 1, 2014. Under the terms of the resulting swap, the University will pay a fixed rate of 4.7% and receive the SIFMA index from October 1, 2014 through October 1, 2039. The University expects to refinance the Series S bonds on their October 1, 2014 call date with proceeds of a new tax exempt variable rate bond issue (Series Y) with amortization and final maturity identical to the existing Series S bonds and hedged with the new interest rate exchange agreement. In addition, the University expects to refinance \$73,400,000 of existing tax exempt fixed rate Series V-2 and V-3 bonds at their maturity on October 1, 2014, funded with proceeds of new five-year tax exempt fixed rate Series Z-1 and Z-2 bonds.

The University has assessed the impact of subsequent events through September 17, 2014, the date the Consolidated Financial Statements were issued.

Supplementary Schedule of Expenditures of Federal Awards

Year ended June 30, 2014

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA number	Federal expenditures
Research and Development Cluster:		
Direct Awards:		
Agency for International Development:	98	\$ 206.673
Agency for International Development Agency for International Development	98 98.001	\$ 206,673 428,586
Agency for International Development Total	70.001	635,259
		033,239
Department of Agriculture: Department of Agriculture	10	25,813
Department of Agriculture	10.310	364,461
Department of Agriculture Total		390,274
Department of Commerce:		270,271
Department of Commerce	11	81.204
Department of Commerce	11.420	(198)
Department of Commerce	11.440	(4,164)
Department of Commerce Total		76,842
Department of Defense:		
Air Force	12	922,363
Air Force	12.800	1,693,958
Air Force	12.910	144,918
Army	12	380,079
Army	12.420	3,311,950
Army	12.431 12.630	1,982,660
Army Army	12.910	361,361 337,577
Defense Threat Reduction Agency	12.351	534,721
Defense Threat Reduction Agency	12.630	86,811
National Security Agency	12.901	19,155
Navy	12	116,127
Navy	12.300	4,574,188
Department of Defense Total		14,465,868
Department of Education:		
Department of Education	84.133	1,761,350
Department of Education	84.305	241,047
Department of Education	84.324	459,311
Department of Education Total		2,461,708
Department of Energy:		
Department of Energy	81.049	4,280,937
Department of Energy	81.087	358,986
Department of Energy	81.089	278,697
Department of Energy	81.135	713,477
National Energy Technology Lab	81.089	119
Department of Energy Total		5,632,216
Department of Health and Human Services:	00.040	****
Administration on Aging	93.048	111,587
Agency for Healthcare Research And Quality	93 93.226	174,850 722,836
Agency for Healthcare Research And Quality Center for Disease Control	93.220	3,444,505
Center for Disease Control	93.135	23,925
Center for Disease Control	93.283	217,626
Center for Disease Control	93.542	585,649
Eunice Kennedy Shriver National Institute of Child Health and Human Development	93.865	5,741,556
Eunice Kennedy Shriver National Institute of Child Health and Human Development – ARRA	93.701	(637)
Fogarty International Center	93.989	33,763
Health Resources and Services Administration	93.110	486,570
Health Resources and Services Administration Health Resources and Services Administration	93.145 93.250	1,269,803 11,027
Health Resources and Services Administration	93.928	455,941
National Cancer Institute	93	335,248
National Cancer Institute	93.310	203,336
National Cancer Institute	93.393	5,053,178
National Cancer Institute	93.394	464,711
National Cancer Institute	93.395	1,202,949
National Cancer Institute	93.396	1,888,291
National Cancer Institute	93.398	227,602
National Cancer Institute National Cancer Institute – ARRA	93.838 93.701	687,845 (6,084)
	73.701	(0,004)
National Center for Complementary and Alternative Medicine	93.213	1,083,547

Supplementary Schedule of Expenditures of Federal Awards

Year ended June 30, 2014

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA number	Federal expenditures
National Center for Health Research Resources	93.350	\$ 3,567,155
National Center for Health Research Resources	93.389	(142,608)
National Center for Health Research Resources – ARRA	93.701	29,798
National Center on Minority Health and Health Disparities	93.307	610,339
National Eye Institute	93.867	2,429,508
National Eye Institute – ARRA	93.701	(166)
National Heart, Lung, and Blood Institute	93	10,964,963
National Heart, Lung, and Blood Institute	93.310	409,319
National Heart, Lung, and Blood Institute	93.837	9,819,628
National Heart, Lung, and Blood Institute	93.838	6,580,644
National Heart, Lung, and Blood Institute	93.839	3,249,483
National Heart, Lung, and Blood Institute – ARRA	93.701	(13,963)
National Human Genome Research Institute	93.172	1,563,702
National Institute of Allergy and Infectious Diseases	93	1,282,461
National Institute of Allergy and Infectious Diseases	93.855	19,503,982
National Institute of Allergy and Infectious Diseases – ARRA	93.701	(2,416)
National Institute of Arthritis and Musculoskeletal and Skin Diseases	93.310	394,394
National Institute of Arthritis and Musculoskeletal and Skin Diseases	93.846	8,348,083
National Institute of Biomedical Imaging and Bioengineering	93.286	3,407,349
National Institute of Dental and Craniofacial Research	93.121	5,720,292
National Institute of Dental and Craniofacial Research – ARRA	93.701	(78,531)
National Institute of Dental and Craniofacial Research – ARRA	93.715	(18,383)
National Institute of Diabetes and Digestive and Kidney Diseases	93.847	6,709,863
National Institute of Environmental Health Sciences	93.113	2,493,859
National Institute of Environmental Health Sciences	93.143	2,629,521
National Institute of General Medical Sciences	93.859	9,753,975
National Institute of General Medical Sciences – ARRA	93.701	(30,030)
National Institute of Mental Health	93.242	9,890,452
National Institute of Mental Health	93.281	121,049
National Institute of Mental Health	93.310	8,563
National Institute of Neurological Disorders and Stroke	93.242	235,300
National Institute of Neurological Disorders and Stroke	93.310	560,615
National Institute of Neurological Disorders and Stroke	93.853	8,721,639
National Institute of Neurological Disorders and Stroke – ARRA	93.701	(60)
National Institute on Aging	93.866	10,484,524
National Institute on Aging – ARRA	93.701	(904)
National Institute on Alcohol Abuse and Alcoholism	93.273	2,159,408
National Institute on Deafness and Other Communication Disorders	93.173	6,279,509
National Institute on Drug Abuse	93.279	1,718,437
NIH Clinical Center	93	895,516
Office of Assistant Secretary for Preparedness and Response	93	286,270
Office of the Director, National Institutes of Health	93.310	570,900
Substance Abuse and Mental Health Service Administration	93.243	224,965
Department of Health and Human Services Total		165,751,542
epartment of Homeland Security: Department of Homeland Security	97.077	83,965
Department of Homeland Security Total		83,965
epartment of Housing and Urban Development:		
Department of Housing and Urban Development	14.906	173,050
Department of Housing And Urban Development Total		173,050

Supplementary Schedule of Expenditures of Federal Awards Year ended June 30, 2014

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA number	Federal expenditures
Department of Justice: Department of Justice Department of Justice	16 \$ 16.560	457,432 44,399
Department of Justice Total	_	501,831
Department of Labor: Department of Labor	17	(5,675)
Department of Labor Total	_	(5,675)
Department of the Interior: Department of Interior Department of Interior Department of Interior	15 15,944 15,979	624,059 70,992 526
Department of the Interior Total	-	695,577
Department of Transportation: Department of Transportation	20.109	184,767
Department of Transportation Total	<u>-</u>	184,767
Department of Veterans Affairs: Department of Veterans Affairs	64	5,029,674
Department of Veterans Affairs Total	_	5,029,674
Environmental Protection Agency: Environmental Protection Agency Environmental Protection Agency	66.509 66.514	321,584 12,906
Environmental Protection Agency Total	_	334,490
Executive Office of the President: Executive Office of the President	95	(20,188)
Executive Office of the President Total	_	(20,188)
National Aeronautics and Space Administration: National Aeronautics and Space Administration National Aeronautics and Space Administration National Aeronautics and Space Administration	43 43.001 43.003	85,384 3,048,434 392,362
National Aeronautics and Space Administration Total	-	3,526,180
National Endowment for the Humanities: National Endowment for the Humanities National Endowment for the Humanities	45.161 47.075	17,802 46,197
National Endowment for the Humanities Total	_	63,999
National Science Foundation: National Science Foundation	47.041 47.049 47.050 47.070 47.074 47.075 47.076 47.078 47.079 47.080 47.082	2,506,898 6,279,360 3,490,046 4,441,558 2,552,198 5,252,776 3,158,382 113,685 87,036 318,254 1,689,023
National Science Foundation Total		29,889,216
Research and Development Direct Awards Total		229,870,595

Supplementary Schedule of Expenditures of Federal Awards

Year ended June 30, 2014

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA number	Pass-through number	Federal expenditures
Research and Development Cluster:		1100000	
Research and Development Pass-through Awards:			
Agency for International Development:	00	ADT ACCOCIATES LIGATE	¢ (2.169)
Abt Associates, Inc. Johns Hopkins University	98 98.001	ABT ASSOCIATESUSAID 106744	\$ (2,168) 149,163
Pharmaccess Namibia	98	41125	23,948
Right To Care	98	Not Available	130,097
Save The Children International In Zambia	98.001	84000825	149,249
United States Pharmacopeial Convention	98.001	GHS-A-00-09-00003-00	164,927
Wits Health Consortium	98.001	HERO-002	195,020
Agency for International Development Total			810,236
Department of Agriculture: Boston Medical Center	10	3182	50,730
Boston Medical Center	10.500	3518	22,770
Impaq International, LLC	10	2151	16,364
Kidscook, LLC	10.212	2012-04061	57,378
University of New Hampshire	10.652	PZ10-0009	1,381
University of Wisconsin	10.255	471K494	30,758
Department of Agriculture Total			179,381
Department of Commerce: University of Maryland	11.440	Z765201	(925)
University of Massachusetts, Boston	11.440	5710002776	12,947
University of Rhode Island	11.417	4055-031414	33,128
University of Rhode Island/Sea Grant Program	11.417	0002470/021613	25,000
University of Rhode Island/Sea Grant Program	11.417	040510/0002476	23,486
Woods Hole Oceanographic Institution	11.417	A100704	9,101
Woods Hole Oceanographic Institution	11.417	A100924	73,569
Department of Commerce Total			176,306
Department of Defense: Bae Systems, Inc.	12	678520	(1,458)
Battelle Memorial Institute	12	PO 356390	28,660
Battelle Memorial Institute	12	Not Available	(90)
Beth Israel Deaconess Medical Center	12.420	MOA dated 7/15/11	(3)
Boston VA Research Institute, Inc.	12.420	1	14,156
Bronx Veterans Medical Research Foundation Charles River Analytics, Inc.	12.420 12	GW110054 SC1105601	58,642 125,309
Charles River Analytics, Inc. Charles River Analytics, Inc.	12	SC1103001 SC1201801	152,918
Charles River Analytics, Inc.	12	SC1224401	37,327
Charles Stark Draper Laboratory, Inc.	12	PO 001-0001026345	7,554
City College of New York	12.800	47194A	52,676
DCG Systems, Inc.	12	IRP3-BU	215,902
Energesis Pharmaceuticals, Inc Hansjorg Wyss Institute for Biologically Inspired Engineering	12 12	W81XWH-11-C-0517 167837-5054561	97,707 58,878
Harvard University	12	167824.0003	467,959
Harvard University	12.420	133160-02	8,693
Henry M. Jackson Foundation	12.420	739614	18,581
Henry M. Jackson Foundation	12.420	W81XWH-11-2-0174	65,435
HRL Laboratories, LLC	12	11090-200926-DS	161,174
Infinium Metals Inc. LGS Innovations, LLC	12 12	N00014-13-P-1138 LGS131140G	39,846 25,571
Longshortway, Inc	12	FA8650-13-M-1564	51,984
Massachusetts Institute of Technology	12	5710003194-04	125,513
Massachusetts Institute of Technology	12.300	5710002582	23,038
Massachusetts Institute of Technology	12.300	5710002632	50,833
Massachusetts Institute of Technology	12.300	5710002645	180,737
Massachusetts Institute of Technology Massachusetts Institute of Technology	12.300 12.431	5710003312 5710003053	97,724 47,534
Massachusetts Institute of Technology – Lincoln Laboratory	12.431	5710003052 7000141894	(12,159)
Neostem, Inc	12.420	W81XWH-10-2-0039	118,406
Neurala, LLC	12	FA8750-12-1-0123	32,216
Northeastern University	12.800	504321	90,367
Photon Systems, Inc.	12.431	035BU	(77,043)
Photonic Glass Corporation	12	FA-9550-10-C-0066	(1,850)
Raytheon Company Science Research Laboratory, Inc.	12 12	9500010646 C-0297-393	66,678 976
Scientific Systems Company, Inc.	12	C-0297-393 1542-B.U.	102,323
Spaceworks, Inc	12	PO-12-7060M-01B	25,043
The Geneva Foundation	12.351	S-1340-01	18,083
The Optical Sciences Company	12	HZ0147-14-C-7908	814

Supplementary Schedule of Expenditures of Federal Awards

Year ended June 30, 2014

ederal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA number	Pass-through number	Federal expenditures
Tufts University	12.431	ARM168	\$ (1,341)
University of California, San Diego	12.800	10312239-SUB	201,975
University of Illinois, Urbana-Champaign	12.300	2013-03174-03 (AA669)	80,558
University of Illinois, Urbana-Champaign	12.800	2010-07331-01	175,653
University of Maryland, Baltimore County	12.910	12012	460,553
University of Massachusetts, Dartmouth	12.300	14270	6,000
University of Michigan	12	3003005118	12,478
University of Rochester	12.431	415338-G	3,933
University of Texas At Austin	12.431	UTA12-001015	338,954
University of Utah	12.630	10028801-BU-APP	500,535
University of Utah	12.630	10028801-BU-BPP	219,287
University of Washington	12.300	705016	600,751
Washington University	12.420	WU-13-62	48,924
Woods Hole Oceanographic Institution	12.300	A100728	(849
Woods Hole Oceanographic Institution	12.300	A101110	5 255 405
Department of Defense Total			5,255,495
Department of Education:	04 101	INTER-011111270-011110	20.246
Commonwealth of Massachusetts Kent State University	84.181 84.133	INTF3601HH2706811119 401006-BU	29,346 45,590
	84.295		152,693
Public Broadcasting Service Temple University	84.305	U295A100025 300132-BU	132,093
Trustees of Dartmouth College	84.133	960	10,627
University of Pittsburgh	84	0024730 (601047-1)	(582
Department of Education Total			252,302
Department of Energy:			
Battelle Energy Alliance, LLC	81	128776	221,487
Battelle Memorial Inst/Pacific Northwest National Laboratory	81	176254	10,710
Battelle Memorial Inst/Pacific Northwest National Laboratory	81	179721	1,169
Battelle Memorial Inst/Pacific Northwest National Laboratory	81	225805	7,945
Columbia University	81	6 (GG009028)	100,359
Decision Detective Corporation	81.049	DESC0006262	41,125
Fermi National Accelerator Laboratory	81	611002	24,478
Fermi National Accelerator Laboratory	81	613421	65,178
Fermi National Accelerator Laboratory	81	613881	32,000
Fermi National Accelerator Laboratory	81	616060	6,549
Fermi National Accelerator Laboratory	81	PO 606923	34,774
Fermi National Accelerator Laboratory	81	PO 610132	(1,328
Fermi National Accelerator Laboratory	81 81	PO 611357	64,336
Fermi National Accelerator Laboratory	81 81	PO 615323	3,850 219,416
Fermi National Accelerator Laboratory	81.049	Not Available	93,724
Fermi National Accelerator Laboratory	81.049 81.049	607489	213,187
Harvard University Infinium Metals Inc.	81.049	133183-5041151 DE-AR0000412	69,989
Los Alamos National Laboratory	81	214476	31,157
	81.086	DE-EE0005547	37,738
Moxst, Inc. Pennsylvania State University	81.049		50,655
Sandia National Laboratories	81.049 81	4331-BU-SU-9105 1222895	50,653 77,506
Sandia National Laboratories Sandia National Laboratories	81	1344135	34,866
URS Energy & Construction	81	RES1301924	28,409
URS Energy & Construction	81	RES1301924 RES1302658	36,061
UT-Battelle, LLC/Oak Ridge National Laboratory	81	4000091123	5,479
	81	4000127105	29,993
UT-Battelle, LLC/Oak Ridge National Laboratory Xradia Corp	81.049	DE-SC0009733	61,074
Department of Energy Total			1,601,886
Department of Health and Human Services:			
Acetylon Pharmaceuticals, Inc.	93.837	NHLBI-Acetylon-BU	167,686
Acpharis, Inc.	93.859	1R41GM097907-01	(103
Acpharis, Inc.	93.859	1R41GM101907	5,611
Agiltron, Inc	93.113	NIH1018001II	127,090
Albert Einstein College of Medicine	93.866	9-526-2762	(449
Allina Health System	93.213	1 R21 AT003315-01A2	(117
American Heart Association	93.077	FX-ATRAC-BU-01	118,209
Arthritis Foundation	93.068	DP003828	9,99
Beth Israel Deaconess Medical Center	93.173	1026514	206,710
Beth Israel Deaconess Medical Center	93.213	1026085	17,263
Beth Israel Deaconess Medical Center	93.286	1025934	87,386
	93.286 93.393	1025934 1027119	87,386 53,044

Supplementary Schedule of Expenditures of Federal Awards

Year ended June 30, 2014

eral Grantor/Pass-through Grantor/Program or Cluster Title	CFDA number	Pass-through number	Federal expenditures
Beth Israel Deaconess Medical Center	93.395	057-816-4435-5	\$ (7,268)
Beth Israel Deaconess Medical Center	93.846	1026873	60,650
Biohelix Corporation	93.855	1R41AI092913-01	31,013
Board of Trustees of The Leland Stanford Junior University	93	23057560-41466-F	262,154
Boston College	93.855	1520-1	(316)
Boston College	93.865	1521-1	18,428
Boston Medical Center	93	2344	70,586
Boston Medical Center	93.104	3638 333701	8,062
Boston Medical Center	93.121 93.121	333701 3816	114,188
Boston Medical Center Boston Medical Center	93.136	286302	35,158 (315)
Boston Medical Center	93.242	1793	14,546
Boston Medical Center	93.273	3014	83,883
Boston Medical Center	93.279	326901	36,990
Boston Medical Center	93.279	1991	125,136
Boston Medical Center	93.279	1992	137,561
Boston Medical Center	93.279	2115	127,198
Boston Medical Center	93.279	2138	92,958
Boston Medical Center	93.279	2563	277,660
Boston Medical Center	93.279	2765	14,373
Boston Medical Center	93.283	2370	16,169
Boston Medical Center	93.393	268301	(7,651)
Boston Medical Center	93.393	1592	29,573
Boston Medical Center	93.395	2165	(218)
Boston Medical Center	93.837	1869	239,829
Boston Medical Center	93.837	3985	45,897
Boston Medical Center	93.838	2309	67,552
Boston Medical Center	93.839	2139	160,814
Boston Medical Center	93.847	187011	22,111
Boston Medical Center Boston Medical Center	93.847 93.847	2616 2620	22,168 23,668
Boston Medical Center	93.847	2819	5,904
Boston Medical Center	93.853	1783	30,726
Boston Medical Center	93.855	325401	82,436
Boston Medical Center	93.866	252701	(364)
Boston Medical Center	93.866	1857	7,260
Boston Medical Center	93.866	2133	23,009
Boston Medical Center	93.866	2189	30,101
Soston Medical Center	93.866	2533	151,370
Boston Medical Center	93.866	2579	36,282
Soston Nutrition Obesity Research Center	93.847	3809	9,756
Brandeis University	93.575	402283	33,197
Brandeis University	93.866	4-02075	13,406
Brigham and Women's Hospital	93	101949	43,843
Brigham and Women's Hospital	93.172	106933	58,859
Brigham and Women's Hospital	93.172	107049	966
Brigham and Women's Hospital	93.279	108285	11,094
Brigham and Women's Hospital	93.838	104228	325,165
Brigham and Women's Hospital	93.838	106776	103,694
Brigham and Women's Hospital	93.846	108331	73,305
Brigham and Women's Hospital	93.846	109379	75,527
Brigham and Women's Hospital	93.847 93.855	108909 104684	67,154 2,641
Brigham and Women's Hospital Brigham and Women's Hospital		110233	10,524
Brigham and Women's Hospital	93.855		7,894
Brigham and Women's Hospital	93.864 93.865	104182 143891	(47)
Brigham and Women's Hospital	93.866	109517	15,248
Brigham and Women's Hospital	93.866	109317	73,820
Broad Institute	93.847	520346-5500000592	110,866
Brown University	93.242	474	7,202
Butler Hospital	93.242	9032-8311	17,196
California Pacific Medical Center	93.866	2803226-S160	46,355
Carmot Therapeutics, Inc.	93.395	2R44CA153676-02	82,516
Casa Esperanza, Inc.	93.243	1H79TI024693-01	41,596
Casa Esperanza, Inc.	93.243	1H79TI025272-01	86,090
Case Western Reserve University	93.867	RES508494	26,524
Children's Hospital, Boston	93.837	326029	(100)
Children's Hospital, Boston	93.847	535928	157,894
Children's Hospital, Boston	93.855	PO RSTFD0000540521	24,508
Children's Hospital, Seattle	93.838	10215SUB	15,923
Cincinnati Children's Hospital Medical Center	93.837	109363	488

Supplementary Schedule of Expenditures of Federal Awards

Year ended June 30, 2014

eral Grantor/Pass-through Grantor/Program or Cluster Title	CFDA number	Pass-through number	Federal expenditur
Cleveland Clinic Foundation	93.847	308-SUB	\$ 122,98
Cleveland Clinic Lerner College of Medicine of Case Western	93	HHSN268200700018C	14,96
Colorado State University	93.855	G-4887-2	16,02
Columbia University	93.390	G03506	25,17
Columbia University	93.394	1 (GG004019)	61,32
Columbia University	93.394	1 (GG004958)	23,69
Commonwealth of Massachusetts	93	INTF3122HH2W97913014	76,13
Commonwealth of Massachusetts	93	INTF6207HH4300522527	(1,64
Commonwealth of Massachusetts	93.074	INTF6208HH4300522127	335,99
Commonwealth of Massachusetts – Department of Public Health	93	200-2001-00082	(2,48
Commonwealth of Massachusetts – Department of Public Health	93.077	INTF122HH2706811032	116,15
Dana-Farber Cancer Institute	93.172	1158102	40
Dana-Farber Cancer Institute	93.396	1187905	(3,23
Dartmouth College	93.242	1257	14,24
Dartmouth College	93.859	1281	230,04
Dartmouth College	93.999	791	41,75
Dimagi, Inc.	93	DIMAGI INCNIH NCI	1.466.76
Duke University	93	2031988	1,466,73
Duke University	93	HHSN272201100025C	10,46
Duke University	93.837	203-9989	42,09
Duke University	93.838	203-9813	25,70
Duke University	93.855	2031952	(72,32
Duke University	93.855	2032065	85,55
Duke University	93.855	2032655	316,94
East Carolina University	93.242	A11-0125-S003	20,23
Evanston Northwestern Healthcare Research Institute	93	EH03-339-S4	
Feinstein Institute for Medical Research	93	BOS-01-NON-ARRA	59,13
Fenway Community Health Center	93.865	BU176-3	23,10
Forsyth Institute	93.307	006964-BUMC2390	(11,95
Fraunhofer USA	93.855	3358-SUBA	141,39
Fraunhofer USA	93.855	3358-SUBC	72,72
Genetic Alliance	93.110	U22MC04100	2,3
George Washington University	93.262	13-M95	22,5
Georgetown University	93.393	RX 4442-003-BU	45,0
Georgetown University	93.866	RX2462-189-BU	45,34
Georgia Institute of Technology	93.855	RC670-G1	71,4
Georgia Regents University	93.847	25732-19	50,78
Georgia Regents University	93.855	23069-38	113,39
Griffin Laboratories, Inc	93.173	2R42DC011212-02	33,98
Harvard School of Public Health	93.061	116198 – Project 1	(22
Harvard School of Public Health	93.135	5031928-114855	7,98
Harvard School of Public Health	93.859	114041.5027	45,83
Harvard School of Public Health	93.859	23570-114041	(19
Harvard School of Public Health	93.864	23570-114045	247,23
Hebrew Rehabilitation Center for the Aged	93.846	10.10.90038	8:
Hebrew Rehabilitation Center for the Aged	93.846	90054	129,6
Hebrew Rehabilitation Center for the Aged	93.866	10.10.90049	35,3
Hebrew Rehabilitation Center for the Aged	93.866	10.10.90053	87,8
Hebrew Rehabilitation Center for the Aged	93.866	90060	5,9
Hebrew Seniorlife	93.846	10.10.90052	(4,2
Hektoen Institute For Medical Research, L.L.C.	93.855	50612-324-BU1-AI034993	31,8
Hektoen Institute For Medical Research, L.L.C.	93.855	50667-324-BU-AI034993-S1	43,6
Henry Ford Health System	93.393	B40540	7,2
Henry Ford Health System	93.393	R01CA140754-04	19,6
Indiana University	93.242	IN-4694751-BU	13,6
Indiana University	93.847	IN4694015BU	104,3
Jackson Laboratory	93.856	201719	27,0
JBS International, Inc.	93	541712	
Johns Hopkins University	93.273	2001374983	462,6
Johns Hopkins University	93.397	2002014652	22,0
Johns Hopkins University	93.848	8202-80102-6	(4
Johns Hopkins University – ARRA	93.701	3R01 DK076770-04S1	(3,00
Joslin Diabetes Center	93.847	Sub_P30DK036836_Kasif	362,7
Joslin Diabetes Center	93.847	Sub_P30DK036836_P&F	46,0
JSI Research Training Institute Inc	93.928	INTF4971M04603614082	102,9
JSI Research Training Institute Inc	93.940	INTF4971M04603614082	24,6
Judge Baker Children's Center (Harvard Affiliate)	93.242	47000-12000-47777	(2,20
Kaiser Permanente – ARRA	93.701	115-9155-01-M1	(43,22
KBD, Inc.	93.866	1R43AG030246-01A2	(9,42
Legacy Research	93.853	MH083973	37,1
Begue's Research			
Mass Eye and Ear Infirmary	93.173	5R01DC005775-09	28,50

Supplementary Schedule of Expenditures of Federal Awards

Year ended June 30, 2014

eral Grantor/Pass-through Grantor/Program or Cluster Title	CFDA number	Pass-through number	Federal expenditures
Massachusetts General Hospital	93.242	216307	\$ 66,387
Massachusetts General Hospital	93.242	216648	121,354
Massachusetts General Hospital	93.242	223260	47,788
Massachusetts General Hospital	93.242	218390	14,993
Massachusetts General Hospital	93.286	221149	139,194
Massachusetts General Hospital	93.837	218179	136,914
Massachusetts General Hospital	93.837	222359	298,340
Massachusetts General Hospital	93.838	205123	6,601
Massachusetts General Hospital	93.847	207092	(5,217)
Massachusetts General Hospital	93.847	218446	379,816
Massachusetts General Hospital	93.847	221228	19,791
Massachusetts General Hospital	93.847	223192	63,251
Massachusetts General Hospital	93.853	208128	(427)
Massachusetts General Hospital	93.854	MGHNIH NINDS	(116)
Massachusetts General Hospital	93.854	MGHNINDS	(40,850)
Massachusetts Institute of Technology	93.173	5710003037	153,773
Massachusetts Institute of Technology	93.397	5710003443	54,742
Massachusetts Institute of Technology	93.853	5710003080	23,225
Massachusetts Institute of Technology	93.855	5710003335	61,593
Mattek Corporation	93.855	1R21A1104385-02A1	81,965
Mattek Corporation	93.855	UAI070914A	(3)
Mayo Clinic	93	MCRN-0054-CPN	12,435
Mayo Clinic	93.867	MAYO CLINICNIH NEI	(58)
Methodist Hospital Research Institute Houston	93.397	27010012-0008	14,258
Mt. Sinai School of Medicine	93.866	0255-3171-4609	165,264
National Committee For Quality Assurance	93	Not Available	15,257
National Jewish Health – ARRA	93.701	NATIONAL JEWISH HEALTH	(759)
Neostem, Inc	93.846	1R43AR062432-01A1	72,308
New England Research Institutes	93.847	NIDDK-NERI-BU	55,557
New England Research Institutes	93.866	NIA-NERI-BU	(6,922)
New Jersey Institute of Technology	93.286	R01-EB009100	(2,202)
New York University	93.307	F7447-01	92,835
New York University School of Medicine	93.859	PA 07-0585	(494)
Northern California Institute For Research And Education	93.242	VIN1478-02	15,403
Northwestern University	93.173	SP0019717-PROJ0004965	165,771
Northwestern University	93.865	SP0019717-FROJ0004903 SP0014607-PROJ0004971	34,780
Northwestern University	93.866	60034742 BU	99,579
Northwestern University	93.867	SP0004560/PROJ0001556	56,666
Oklahoma Medical Research Foundation	93.855	5 U19 AI062629-07	284,429
	93.866	P0330A-A	85,107
Oregon State University Phoenicia Biosciences, Inc.	93.395	R43CA153474-01A1	
Phoenicia Biosciences, Inc.	93.837	1R41 HL108515-01A1	(1) 116,493
	93.859	R41 GM101869-01A1	60,578
Phoenicia Biosciences, Inc.	93.242		
Places for People		BU110607IMR-3	19,390
President And Fellows of Harvard College	93.113	112116.5039	5,019
President And Fellows of Harvard College	93.279	152373.5073034.0002	9,036
President And Fellows of Harvard College	93.292	5044460-114897	38,804
President And Fellows of Harvard College	93.838	113063-5037484	44,014
President And Fellows of Harvard College	93.866	AG008812	(8,096)
Professional & Scientific Associates	93	118678	117
Prothera, Inc.	93.855	5R42 A1062095-05	62,038
Public Health Institute	93.273	1016104R	(3,719)
Purdue University	93.866	4102-45155	(6,484)
Roswell Park Cancer Institute	93.393	63-01	937,737
RTI International	93	1-312-0213520-51349L	41,235
RTI International	93	13-312-0209853	(4,898)
Rutgers University	93.286	PO S1889249	127,640
Schepens Eye Research Institute	93.867	1DP2OD006649-SUB2	31,828
Scimetrika	93	HHSN272201100025C	20,900
Seattle Institute For Biomedical And Clinical Research – ARRA	93.701	BJ18-BOSTON-ARRA	(62)
Simbex, LLC	93.865	R24HD065703	25,269
Spaulding Rehabilitation Hospital	93.837	500173	(11)
Spaulding Rehabilitation Hospital	93.866	500187	99,625
Tapestry Health Systems, Inc.	93.243	HIV OATTS	73,643
	93.110	960676RSUB	3,488
The Children's Hospital of Philadelphia		ACTIVITY 320896	16,109
	93 110	110111111 320070	10,109
The Children's Hospital of Philadelphia	93.110 93.242	126191	(6)
The Children's Hospital of Philadelphia The Children's Hospital of Philadelphia The Institute of Living The Pagents of The University of California	93.242	126191 108731	(6) 8 005
The Children's Hospital of Philadelphia The Institute of Living The Regents of The University of California	93.242 93	108731	8,095
The Children's Hospital of Philadelphia The Institute of Living The Regents of The University of California The Regents of The University of California	93.242 93 93.866	108731 PO 10323238	8,095 (1,965)
The Children's Hospital of Philadelphia The Institute of Living The Regents of The University of California	93.242 93	108731	8,095

Supplementary Schedule of Expenditures of Federal Awards

Year ended June 30, 2014

eral Grantor/Pass-through Grantor/Program or Cluster Title	CFDA number	Pass-through number	Federal expenditure
Tufts – New England Medical Center	93	5005911-SERV	\$ 15,660
Fufts – New England Medical Center	93.837	5007361-SERV	82,989
Tufts – New England Medical Center	93.846	5004324-SERV	27,982
Tufts - New England Medical Center	93.859	5009023-SERV	69,518
Tufts University	93.113	P01ES011624	35,255
Tufts University	93.121	5U01DE017788-05	(548
Tufts University	93.286	HS4976	309,773
Tufts University Tufts University	93.837 93.855	HS2037 HS1371	104,275 41,364
University of Alabama	93.833	38408	7,715
University of Alabama	93.837	000393678-001	103,400
University of British Columbia	93.853	F09-04856	(61,032
University of California, Irvine	93.113	2012-2845	7,01
University of California, Los Angeles	93.393	1562GQB312	315,63
University of California, Los Angeles	93.394	1562 G QB844	42,67
University of California, Los Angeles	93.394	1562GNC385	308,65
University of California, Los Angeles	93.866	150052.5014357.0010	410
University of California, Riverside	93.866	S-000369	2,31:
University of California, San Diego	93.866	10304007-004	31,44
University of California, San Diego	93.866	UC SAN DIEGONIH NIA	6,40
University of California, San Francisco	93.928 93.859	6767sc COEUS 008632-003	87,90 20,65
Jniversity of Cincinnati Jniversity of Colorado, Denver	93.853	FY14.414.001	3,75
Jniversity of Colorado, Denver Jniversity of Colorado, Denver	93.853	PO 1000105902	144,37
University of Connecticut	93.213	7067	83,43
University of Florida	93.847	UF10103	(1,15)
University of Illinois, Urbana-Champaign	93.859	2010-00365-03	185,05
University of Kansas	93.866	FY2010-040-M3	43,90
University of Louisville	93.866	09-1398	(3,82)
Jniversity of Maryland, Baltimore County	93.837	101330A	132,12
Jniversity of Massachusetts, Medical School	93.846	6143085/RFS2013012	29,09
University of Massachusetts, Medical School	93.855	WA00130973/RFS2014040	59,14
Jniversity of Massachusetts, Medical School	93.865	WA00117816/RFS2014022	56,52
University of Massachusetts, Worcester	93.846	WA00112562/RFS2014007	101,05
Jniversity of Massachusetts, Worcester	93.846	WA00118839/RFS2013013	301,31
Jniversity of Massachusetts, Worcester	93.855	WA00130936/RFS2014037	331,39
Jniversity of Mississippi	93.837 93	67841-BU04 66102690414-04BU	117,939 42,150
Jniversity of Mississippi Medical Center Jniversity of Mississippi Medical Center	93.837	66102090414-04BU 66100160213-BU	89,48
Jniversity of New Mexico	93.859	889265-8710	(60
University of Oklahoma	93.855	AA-5-46173	95,07
Jniversity of Pennsylvania	93.103	559467	3,49
University of Pennsylvania	93.837	559908	15,74
University of Pennsylvania	93.837	561970	180,52
Jniversity of Pennsylvania	93.837	561160	108,97
University of Pennsylvania	93.846	560224	10,92
University of Pennsylvania	93.846	562000	116,41
University of Pennsylvania	93.866	563259	532,88
University of Puerto Rico	93.389	3 P40 RR003640-23S1	(2,33
University of Rochester	93.855	415558-G	24,85
University of Rochester	93.999	415158-G	22.42
University of Southern California	93.859	47735772	33,43
University of Texas	93.859 93.701	0009483A UTA09-001041	66,78 (14,60-
University of Texas – ARRA University of Texas At Austin	93.279	UTA14-000122	15,68
University of Texas At Austin University of Texas Health Science Center, San Antonio	93.394	155028	116,02
University of Texas Medical Branch	93.865	13-097	14,36
University of Texas Medical Branch – ARRA	93.701	UOSPC-0000000549	(10,97
University of Texas Southwestern Medical School – ARRA	93.701	GMO-100905	(6,47
University of Utah	93.396	10026603-2	141,81
University of Utah	93.837	10022504-00	22,92
University of Vermont	93.837	25337 BOSTON UNIVERSITY	9,02
University of Vermont – ARRA	93.701	24807 Amendment 2	13,74
University of Washington	93.242	730860	21,03
University of Washington	93.273	736376	70
University of Washington	93.393	716776	5,55
University of Washington	93.837	749258	46,40
University of Washington	93.837	756861	23,51
	93.837	740599	117,21
University of Washington	93.837	759444	3,26
University of Washington University of Washington University of Washington University of Washington		759444 646910 752694	3, 31, 45,

Supplementary Schedule of Expenditures of Federal Awards

Year ended June 30, 2014

Sederal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA number	Pass-through number	Federal expenditures
University of Washington – ARRA	93.701	675144Z	\$ (290)
University of Wisconsin	93.394	188K661	92,624
University of Wisconsin	93.856	X561164	1,466,610
University of Wisconsin	93.866	399K873	2,346
Vanderbilt University	93.394	VUMC38556	2,768
Vanderbilt University	93.847	VUMC30937	686
Veterans Affairs Medical Center of Washington DC	93	688-D42019	15,962
Veterans Medical Research Foundation	93.242	08152-02-311175	40,128
Washington University	93.837	WU-12-93	(156,489)
Washington University	93.837	WU-13-91	106,059
Washington University	93.837	WU-14-110	116,465
Washington University	93.837	WU-14-244-MOD-1	5,988
Washington University	93.847	WU-11-196-MOD-4	168,147
Washington University	93.855	WU-13-111	50,323
Washington University	93.865	WU-14-121	97,616
Washington University	93.865	WU-14-144	104,325
Washington University	93.866	WU-14-311	6,000
Wave 80 Biosciences, Inc.	93	W802010001	68,805
Westat, Inc.	93	6182-S02	50,000
Whitehead Institute for Biomedical Research	93.395	11-1766-9902	219,882
Yale University	93.226	M13A11548 (A09061)	108,386
Yale University	93.279	M14A11732 (A09415)	147,344
Yale University	93.310	C11A10967	9,866
Yale University – ARRA	93.701	M10A10467 (AS0190)	(1,445)
Zoiray Technologies, Inc.	93.847	R43 DK083167-01	(927)
Department of Health and Human Services Total			23,049,236
Department of Homeland Security:			
Ionsense, Inc.	97	HSHQDC-13-C-B0025	13,192
Northeastern University	97	504996-78051	42,232
Northeastern University	97	505020	24,653
Northeastern University	97.061	504928P0902638	181,737
Northeastern University	97.061	504987-78050	20,347
Northeastern University	97.061	504989	(461)
Northeastern University	97.061	505035-78050	194,639
Department of Homeland Security Total			476,339
Department of Housing and Urban Development: Boston Public Health Commission	14	ВРНС	7,387
Department of Housing and Urban Development Total			7,387
Department of Justice:			
Boston Medical Center	16.560	3984	2,265
Portland State University	16.726	203KEL366	13,881
University of Maryland	16.734	Z918501	102,290
University of Massachusetts, Boston	16.726	Not Available	3,452
Department of Justice Total			121,888
Department of Labor:			· · · · · · · · · · · · · · · · · · ·
Înstitute For Educational Leadership	17.720	2010-07331-01	103,708
Department of Labor Total			103,708
Department of the Interior:	4=		. = - :
Massachusetts Institute of Technology	15	5710003509	17,999
University of Massachusetts, Amherst	15.805	11-006501 E 00	4,960
University of Washington	15.945	2013NPS George M. Wright Fellowship	5,804
Department of the Interior Total			28,763
Department of the Treasury: Boston Medical Center	21	93354	(231)
Department of the Treasury Total			(231)
Department of Transportation:			
Harvard University	20	112413-5042723-0007	27,911
Department of Transportation Total			27,911
Department of Veterans Affairs: National Academy of Sciences	64	IOM – 2000002826	21,980
			21 000
Department of Veterans Affairs Total			21,980
Department of Veterans Affairs Total Environmental Protection Agency:			
-	66.437	2013-039	21,980

Supplementary Schedule of Expenditures of Federal Awards

Year ended June 30, 2014

ederal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA number	Pass-through number	Federal expenditure
National Aeronautics and Space Administration:			
Atmospheric And Environmental Research, Inc	43	P1864-001	\$ 34,178
Boston Micromachines Corporation	43	NNX11CB22C	54,120
Boston Micromachines Corporation	43	NNX10CE08P	(834
Jet Propulsion Laboratory	43 43	1259071	47,748
Jet Propulsion Laboratory Jet Propulsion Laboratory	43	1439600 1472312	2,769 140,154
Jet Propulsion Laboratory	43	1500040	36,798
Jet Propulsion Laboratory	43	1503094	20
Jet Propulsion Laboratory	43	RSA No. 1440385	16,050
Johns Hopkins University Applied Physics Laboratory	43	103473	23,06
Johns Hopkins University Applied Physics Laboratory	43	923497	(2,301
Montana State University	43.001	G143-14-W3913	8,250
National Space Biomedical Research Institute	43.002	NCC 9-58-130	16,052 101.102
Neurala, LLC Oregon State University	43 43.001	NNX13CL63C NS239A-A	41,41
Pennsylvania State University	43.001	4719-BU-NASA-J02G	8,20
Space Telescope Science Institute	43.001	1220	11,834
Space Telescope Science Institute	43.001	E99019MO	10,99
Space Telescope Science Institute	43	HST-GO-11970.01-A	(622
Planetary Science Institute	43	HST-GO-12176.01-A	37,62
Southwest Research Institute	43	HST-GO-12235.01-A	(2
Space Telescope Science Institute	43	HST-GO-12538.01-A	15,20
Space Telescope Science Institute	43	HST-GO-12601.01-A	34,63
Space Telescope Science Institute	43	HST-GO-12883.01-A	11,35
Space Telescope Science Institute	43	HST-GO-13012.01-A	32,05
Space Telescope Science Institute	43 43	HST-GO-13047.01-A HST-GO-13329.01-A	24,45
Space Telescope Science Institute Space Telescope Science Institute	43	HST-GO-13329.01-A HST-GO-13396.001-A	40,64 10,04
Space Telescope Science Institute Space Telescope Science Institute	43	1000320450	41,39
Space Telescope Science Institute Space Telescope Science Institute	43.002	1000025587	53,90
Space Telescope Science Institute	43.001	S20130000022528	97,45
University of Colorado	43.001	S5200000022032	37,00
University of Colorado	43.001	397K740	39,23
University of Massachusetts, Boston	43.001	WHRC-JG0866-01	42,64
National Aeronautics and Space Administration Total			1,066,64
National Science Foundation: Adicep Technologies	47.041	IIP-1152605	57,38
Administrators of the Tulane Educational Fund – ARRA	47.041	TUL-588-09/10	24,16
Aeolus Building Efficiency	47.041	IIP-1346436	25,82
Boston Medical Center	47.079	3772	5,24
Columbia University	47.049	1 (GG006141)	220,26
Columbia University	47.049	2 (Acct. 5-24324)	(1,47
Columbia University	47.049	2 (GG006141)	555,08
Consortium For Ocean Leadership	47	T346B6	56,72
Consortium For Ocean Leadership	47.050	PO T329A6	(5,90
Consortium For Ocean Leadership	47.050	PO T333A6	1,63
Consortium For Ocean Leadership	47.050	T346A6	10,13
Cornell University Education Development Center Inc	47.074 47.076	61468-10043 11479	16,75 33,63
Fast Ceramics LLC	47.076	1315774	52,20
Gallaudet University	47.041	Not Available	(1,04
Johns Hopkins University	47.049	2001597619	5.00
Massachusetts Institute of Technology	47.050	5710003379	69,04
Massachusetts Institute of Technology	47.050	5710003495	4,91
National Radio Astronomy Observatory	47.049	SOSP12A-009	17,13
Northeastern University	47.041	400013P104935	(88
Northwest Research Associates, Inc.	47.050	NWRA-09-S-121	(1
Pennsylvania State University	47.050	4754-BU-NSF-0507	105,50
Pennsylvania State University	47.075	4676-BU-NSF-7440	77,15
Physics Teacher Education Coalition (Phystec)	47.049	MOU DTD 7-31-13	79,30
President And Fellows of Harvard College	47.074	131706-5056666	32,69
Raytheon Bbn Technologies Corp.	47.070 47.041	9500012010 A12020	30,87 635.40
Rensselaer Polytechnic Institute Rutgers University	47.041 47.076	A12020 4204	635,40 30,15
State University State University of New York At Stony Brook	47.076 47.041	58149-1096358-2	30,13
University of California, Davis	47.041 47.049	09000769-BU	90,00
University of California, Davis University of California, Los Angeles	47.049	1000 G HD770	(13,08
University of Camorina, Los Angeles University of Cincinnati	47.076	8932	20,24
University of Colorado	47.071	1000049858	(4,18)

Supplementary Schedule of Expenditures of Federal Awards

Year ended June 30, 2014

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA number	Pass-through number	Federal expenditures
University of Illinois, Urbana-Champaign	47.070	2013-01010-02	\$ 33,390
University of Illinois, Urbana-Champaign	47.074	2011-00975-01	106,326
University of Illinois, Urbana-Champaign	47.078	2010-03733-02	1,258
University of Massachusetts, Amherst	47.076	05-003146 G 07	4,944
University of Massachusetts, Amherst	47.076	11006701A00	4,140
University of Virginia	47.074	GA10618-127104	15,583
University of Virginia	47.074	GA11020-142303	5,368
University of Wisconsin	47.076	406K055	20,806
Vanderbilt University – ARRA	47.082	20743-51	(15)
National Science Foundation Total Research and Development Pass-through Total			2,444,035
Research Training Direct Awards:			35,648,117
Department of Defense:			
National Security Agency	12.900		72,833
National Security Agency	12.901		33,000
National Security Agency	12.902		119,102
Department of Defense Total			224,935
Department of Education:	94.015		260.700
Department of Education	84.015 84.022		260,728
Department of Education	84.022 84.063		66,146 13,480
Department of Education Department of Education	84.133		894,893
Department of Education Department of Education	84.200		209,698
Department of Education Total	04.200		1,444,945
•			1,444,743
Department of Health and Human Services: Eunice Kennedy Shriver National Institute of Child Health and			
Human Development	93.865		528,731
Health Resources and Services Administration	93.110		206,271
Health Resources and Services Administration	93.516		301,562
Health Resources and Services Administration	93.732		174.306
Health Resources and Services Administration	93.884		178,139
Health Resources and Services Administration	93.924		684,352
National Cancer Institute	93.398		487,421
National Center for Health Research Resources	93.350		(6,065)
National Center for Health Research Resources	93.389		(6,236)
National Center for Health Research Resources – ARRA	93.701		(60)
National Heart, Lung, and Blood Institute	93.837		1,296,833
National Heart, Lung, and Blood Institute	93.838		743,858
National Heart, Lung, and Blood Institute	93.839		235,523
National Institute of Allergy and Infectious Diseases	93.855		1,003,709
National Institute of Arthritis and Musculoskeletal and Skin Diseases National Institute of Biomedical Imaging and Bioengineering	93.846 93.286		437,791 112,991
National Institute of Diabetes and Digestive and Kidney Diseases	93.847		30,202
National Institute of Environmental Health Sciences	93.113		156,780
National Institute of General Medical Sciences	93.859		1,461,734
National Institute of Mental Health	93.242		451,529
National Institute of Mental Health	93.282		26,000
National Institute of Neurological Disorders and Stroke	93.853		240,469
National Institute on Aging	93.866		471,110
National Institute on Deafness and Other Communication Disorders	93.173		143,160
National Institute on Drug Abuse	93.279		144,731
Office of the Director, National Institutes of Health	93.351		159,465
Department of Health and Human Services Total			9,664,306
Environmental Protection Agency: Environmental Protection Agency	66.514		40,513
Environmental Protection Agency Total			40,513
National Aeronautics and Space Administration:			
National Aeronautics and Space Administration	43.001		110,972
National Aeronautics and Space Administration	43.008		75,463
National Aeronautics and Space Administration Total			186,435

Supplementary Schedule of Expenditures of Federal Awards

Year ended June 30, 2014

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA number	Pass-through number	Federal expenditures
National Science Foundation: National Science Foundation National Science Foundation	47.041 47.076		\$ 66,021 85,209
National Science Foundation Total			151,230
Research Training Direct Awards Total			11,712,364
Research Training Pass-through Awards: Department of Defense Draper Laboratory, Inc. Institute of International Education Institute of International Education	12 12.357 12.357	P001-0001029956 2013-GO-BU 2012-GO-BU	33,633 153,902 265,091
Department of Defense Total			452,626
Department of Education: Commonwealth of Massachusetts/Department of Elementary and Secondary Education	84.366	150-020-9-3412-J	(7)
Department of Education Total			(7)
Department of Health and Human Services: Association of Maternal And Child Health Programs Boston Medical Center Brigham & Women's Hospital Commonwealth of Massachusetts Dartmouth College Dartmouth College Medical School Harvard University Partners Healthcare System, Inc. University of Massachusetts Memorial Medical Center University of Massachusetts, Worcester University of Massachusetts, Worcester University of Massachusetts, Worcester University of Hassachusetts, Worcester University of Massachusetts, Worcester University of Massachusetts, Worcester University of Massachusetts, Worcester University of Bassachusetts, Worcester Department of Labor: City of Boston Department of Labor Total Department of State:	93.110 93.156 93.846 93.069 93.999 93.889 93.879 93.846 93.107 93.107 93.145 93.145	5-37826 1556 109304 INTF6208HH4300522131 468 1268 151844.5057320.2014 109304, 108152 6126071 WA00143108/RFS2014090 6136286ETC-14 WA00120874-ETC-14	47,188 213,688 34,360 597,166 9,187 27,812 10,063 22,645 (1,113) 29,282 (1,491) 25,483 1,014,270 251,968
Institute of International Education	19.010	S-ECAAS-12-CA-005	26
Department of State Total			26
National Aeronautics and Space Administration: Smithsonian Astrophysical Observatory Space Telescope Science Institute	43.001 43	PF2-130097 HST-HF-51326.01-A	89,325 111,224
National Aeronautics and Space Administration Total			200,549
National Science Foundation: Computing Research Association University of Wisconsin	47.070 47.076	CIF-A-235 490K755	(5,250) 27,978
National Science Foundation Total			22,728
Research Training Pass-through Total			1,942,160
Total Research and Development Cluster			279,173,236
•			

Supplementary Schedule of Expenditures of Federal Awards

Year	ended	June	30,	2014

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA number	Federal expenditures
Student Financial Assistance Programs Cluster: Department of Education: Federal Pell Grant Program Federal Supplemental Educational Opportunity Grants Federal Work Study Teacher Education Assistance for College and Higher Education Grants	84.063 84.007 84.033 84.379	\$ 11,037,130 2,757,706 2,600,643 29,729
Department of Education Total		16,425,208
Student Financial Assistance Programs Cluster Total		16,425,208
Other Program Awards: TRIO Cluster: Trio Direct Programs: Department of Education	84.047	606,457
Department of Education Total		606,457
TRIO Cluster Total		606,457
Child Nutrition Cluster: Child Nutrition Pass-through Programs: Commonwealth of Massachusetts: Department of Agriculture	10.559	18,529
Commonwealth of Massachusetts Total		18,529
Child Nutrition Cluster Total		18,529
Special Education Cluster (IDEA): Special Education Pass-through Programs: Commonwealth of Massachusetts: Department of Education Commonwealth of Massachusetts Total Special Education Cluster Total	84.027	96,025 96,025 96,025
Direct Programs: Agency for International Development Agency for International Development	98.001	225,224
Agency for International Development Total		225,224
Department of Defense: Army	12	190,349
Department of Defense Total		190,349
Department of Education: Department of Education Department of Education	84.015 84.133	138,364 389,918
Department of Education Total		528,282
Department of Energy: Department of Energy Department of Energy Department of Energy Total	81 81.108	214,400 (2) 214,398

$\label{thm:condition} \textbf{Supplementary Schedule of Expenditures of Federal Awards}$

Year ended June 30, 2014

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA number	Federal expenditures
Department of Health and Human Services: Agency for Healthcare Research And Quality Eunice Kennedy Shriver National Institute of Child Health and Human Development Health Resources and Services Administration National Institute of Arthritis and Musculoskeletal and Skin Diseases National Institute of Nursing Research National Institute on Aging NIH Clinical Center Office of the Director, National Institutes of Health	93.226 \$ 93.865 93.928 93.846 93.361 93.866 93	25,741 14,204 79 23,397 (41,480) 45,443 206,995 357,810
Department of Health and Human Services Total		632,189
Department of Justice: Department of Justice	16	77,357
Department of Justice Total		77,357
Department of State Department of State Department of State Department of State	19.014 19.021 19.900	71,000 287,375 3,071
Department of State Total		361,446
Department of Veterans Affairs: Department of Veterans Affairs	64	311,172
Department of Veterans Affairs Total		311,172
National Endowment For The Arts: National Endowment For The Arts	45.024	69,795
National Endowment for the Arts Total		69,795
National Endowment For The Humanities: National Endowment For The Humanities National Endowment For The Humanities National Endowment For The Humanities	45.149 45.160 45.163	102,882 22,199 148,147
National Endowment For The Humanities Total		273,228
National Science Foundation: National Science Foundation National Science Foundation National Science Foundation National Science Foundation	47 47.049 47.070 47.079	66,400 47,631 12,068 1,813
National Science Foundation Total		127,912
Other Program Awards Total		3,732,363

Supplementary Schedule of Expenditures of Federal Awards

Year ended June 30, 2014

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA number	Pass-through number	Federal expenditures
Other Program Awards:			
Pass-through Awards:			
Corporation for National and Community Service	04.006	CETA A A A A A CA TO CHEEN HA A	ф. 51.5 00
Jumpstart For Young Children, Inc.	94.006	CFDA-94.006-JS-SITE #84	\$ 51,589
Corporation for National and Community Service Total			51,589
Department of Defense:			
Beth Israel Deaconess Medical Center	12	US001-0000295807	655
Beth Israel Deaconess Medical Center	12	W81XWH-13-1-0050	32,669
Massachusetts Institute of Technology – Lincoln Laboratory	12	POEM	33,056
Boston VA Research Institute, Inc.	12.420	0072-FEDS-T	136,179
Boston VA Research Institute, Inc.	12.420	0150C	8,960
Boston VA Research Institute, Inc. Henry M. Jackson Foundation	12.420 12.420	CIMIT 11-189, 0159-FEDS-B1 779195	9,878 2,154
Massachusetts General Hospital	12.420	218415	2,134
Department of Defense Total	12.120	210.110	223,550
•			
Department of Education: Boston Medical Center	84.133	239101	(556)
Center for Civic Education	84.304	Not Available	(11)
American Institutes for Research	84.326	313000001	15,460
Department of Education Total			14,893
Department of Energy:			
Battelle Memorial Inst/Pacific Northwest National Laboratory	81	200623	365,187
President And Fellows of Harvard College	81	BA_FY13_DICARLO	27,505
President And Fellows of Harvard College	81	BA_FY13_Sun	24,886
Harvard University Medical School	81.049	SA5283-11210	(11,167)
Department of Energy Total			406,411
Department of Health and Human Services:			
Boston VA Research Institute, Inc.	93	306924	(282)
Boston VA Research Institute, Inc.	93	Interpersonal Agreement	19,107
Center for Social Innovation, LLC	93	BRSS TACS-OY2-BU	5,763
Commonwealth of Massachusetts	93	7213	15,585
Commonwealth of Massachusetts	93	INTF2330M04703015074	72,547
The Lewin Group	93 93	TLG-11-076-5269	112,110
The Lewin Group Commonwealth of Massachusetts	93.069	TLG13056-5176.20 INTF6208HH4005212094	90,958
Commonwealth of Massachusetts – Department of Public Health	93.074	300522	(1,111) 147,659
University of Massachusetts, Worcester	93.172	6145913/RFS2013078	26.857
Casa Esperanza, Inc.	93.243	Tu Bienestar	39,199
Casa Esperanza, Inc.	93.243	H79TI02110	(123)
Casa Esperanza, Inc.	93.243	5H79TI022578-03	37,749
Institute for Health And Recovery, Inc.	93.243	2U79SM059460-04	77,894
Tapestry Health Systems, Inc.	93.243	H79 TI020726	28,956
Tapestry Health Systems, Inc.	93.243	U79SP015081	31,238
Hansjorg Wyss Institute for Biologically Inspired Engineering	93.286	Chen.NIH.UH2	66,264
Massachusetts General Hospital	93.286	220050	34,020
Broad Institute	93.393	2013-BU-4	5,946
Feinstein Institute for Medical Research	93.610	500559-BOS-01	148,456
Boston VA Research Institute, Inc. – ARRA	93.701	5RC2HL101628-02	(38)
Miami University	93.791	G02205	8,755
Massachusetts General Hospital	93.837	216089	4,175
Boston VA Research Institute, Inc.	93.846	Interpersonal Agreement	13,440
Joslin Diabetes Center Joslin Diabetes Center	93.847 93.847	2-20-877-37 BUJRC	2,323 30.000
Joshin Diabetes Center Joshin Diabetes Center	93.847	2P30DK036836	26,095
Boston VA Research Institute, Inc.	93.866	0029-FEDS-A3	7,219
Crecare, LLC	93.866	CRECARE, LLCNIH NIA	(2,851)
Department of Health and Human Services Total			1,047,910

$Supplementary\ Schedule\ of\ Expenditures\ of\ Federal\ Awards$

Year ended June 30, 2014

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA number	Pass-through number		Federal expenditures
Department of State:				
Institute of International Education	19.401	48130689	\$	19,999
Institute of International Education	19.401	48130959	_	22,879
Department of State Total			_	42,878
Leveraging Educational Assistance Partnership (Note 7):				
Commonwealth of Massachusetts	84.069	Not Available		577,500
Commonwealth of Pennsylvania	84.069	Not Available		59,673
State of Connecticut	84.069	Not Available		12,600
State of Delaware	84.069	Not Available		500
State of Pennsylvania	84.069	Not Available		138
State of Rhode Island	84.069	Not Available		30,575
State of Vermont	84.069	Not Available	_	19,425
Leveraging Educational Assistance Partnership Total			_	700,411
National Aeronautics and Space Administration:				
Start International, Inc.	43	NNX11AE35G		26,676
Massachusetts General Hospital	43.001	217923	_	27,783
National Aeronautics and Space Administration Total			_	54,459
Other Program Awards Pass-through Total			_	2,542,101
Other Program Awards Total			_	6,274,464
Total Expenditures of Federal Awards			\$	301,872,908

See accompanying notes to supplementary schedule of expenditures of federal awards.

Notes to Supplementary Schedule of Expenditures of Federal Awards Year ended June 30, 2014

(1) Basis of Presentation

The accompanying supplementary schedule of expenditures of federal awards (the Schedule) summarizes the expenditures of Boston University (the University) under programs of the federal government for the year ended June 30, 2014. The information in this Schedule is presented in accordance with the requirements of U.S. Office of Management and Budget (OMB) Circular A-133, *Audits of States, Local Governments, and Non-Profit Organizations*. Because the Schedule presents only a selected portion of the operations of the University, it is not intended to and does not present the financial position, changes in net assets and cash flows of the University.

For purposes of the Schedule, federal awards include all grants, contracts and similar agreements entered into directly between the University and agencies and departments of the federal government and all subawards to the University by nonfederal organizations pursuant to federal grants, contracts and similar agreements.

(2) Significant Accounting Policies

Expenditures for direct costs are recognized as incurred using the accrual method of accounting and the cost accounting principles contained in OMB Circular A-21, *Cost Principles for Educational Institutions*. Under those cost principles, certain types of expenditures are not allowable or are limited as to reimbursement. Expenditures also include a portion of costs associated with general University activities (facilities and administrative costs) which are allocated to awards under negotiated formulas commonly referred to as facilities and administrative cost rates (note 3). The negative amounts represent adjustments or credits, in the normal course of business, to amounts reported as expenditures in prior years.

(3) Facilities and Administrative Costs

The University has an approved predetermined facilities and administrative cost rate effective through fiscal year June 30, 2014 for on-campus and off-campus sponsored research activities. The base rates in effect for the year ended June 30, 2014 were 63.7% for on-campus research and 26.0% for off-campus research. Facilities and administrative cost recoveries are reported as part of federal expenditures on the Schedule.

Notes to Supplementary Schedule of Expenditures of Federal Awards Year ended June 30, 2014

(4) Federal Student Financial Assistance

Student Loan Programs

The federal student loan programs listed below are administered directly by the University, and balances and transactions relating to these programs are included in the University's consolidated financial statements. Loan activities and balances consist of the following:

Program	Federal CFDA number	 Loans issued during year ended June 30, 2014	Outstanding balance as of June 30, 2014
Perkins Loan Program	84.038	\$ 6,253,035	42,649,788
Medical-Primary Care	93.342	4,700	1,578,475
Health Professions Student Loans (HPSL):			
Medical	93.342	_	4,876
Dental	93.342	142,500	968,332
Loans for Disadvantaged Students (LDS):			
Medical	93.342	20,000	299,564
Dental	93.342	 60,000	512,036
Total		\$ 6,480,235	46,013,071

The University recovered an administrative cost allowance from the Perkins Loan Program (CFDA #84.038) of \$535,757 for the year ended June 30, 2014. There were no new federal capital contributions during the year ended June 30, 2014. Perkins loan cancellations (CFDA #84.037) totaled \$361,563 for the year ended June 30, 2014.

Federal Direct Loans

Federally guaranteed loans distributed to students of the University by the Federal Direct Loan Program during the year ended June 30, 2014 are summarized as follows:

	Federal CFDA number	_	Loans distributed
Federal Direct Stafford Loan Program Federal Direct PLUS Loan Program	84.268 84.268	\$	163,022,994 75,924,064
Total		\$	238,947,058

These distributions and related funding sources are not included in the University's consolidated financial statements.

Notes to Supplementary Schedule of Expenditures of Federal Awards Year ended June 30, 2014

(5) Awards to Subrecipients

Certain funds are provided to subrecipient organizations by the University. The following expenditures incurred by these subrecipients are reimbursed by the University and included on the Schedule for the year ended June 30, 2014:

	_	Total federal expenditures
Research and Development Cluster Other Program Awards	\$	37,271,256 218,305
Total	\$	37,489,561

(6) Leveraging Educational Assistance Partnership

Included on the Schedule under Other Programs, Pass-through Awards are grants (CFDA # 84.069, totaling \$700,411) received from the following states: Massachusetts, Pennsylvania, Connecticut, Delaware, Rhode Island, and Vermont.

None of the states have been able to confirm with the University which portion of the award relates to amounts received from the federal government. Therefore, the University has included the full amounts received from the states on the Schedule.



KPMG LLP Two Financial Center 60 South Street Boston, MA 02111

Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards

The Board of Trustees Boston University:

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the consolidated financial statements of Boston University and its subsidiaries (the University), which comprise the consolidated statement of financial position as of June 30, 2014, the related consolidated statements of activities and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated September 17, 2014.

Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered the University's internal control over financial reporting (internal control) to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, we do not express an opinion on the effectiveness of the University's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.



Compliance and Other Matters

As part of obtaining reasonable assurance about whether the University's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the determination of the consolidated financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the University's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.



September 17, 2014



KPMG LLP Two Financial Center 60 South Street Boston, MA 02111

Independent Auditors' Reports on Compliance for Each Major Federal Program and on Internal Control Over Compliance

The Board of Trustees Boston University:

Report on Compliance for Each Major Federal Program

We have audited Boston University's (the University's) compliance with the types of compliance requirements described in the *OMB Circular A-133 Compliance Supplement* that could have a direct and material effect on each of the University's major federal programs for the year ended June 30, 2014. The University's major federal programs are identified in the summary of auditors' results section of the accompanying schedule of findings and questioned costs.

Management's Responsibility

Management is responsible for compliance with the requirements of laws, regulations, contracts, and grants applicable to its federal programs.

Auditors' Responsibility

Our responsibility is to express an opinion on compliance for each of the University's major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and OMB Circular A-133, *Audits of States, Local Governments, and Non-Profit Organizations*. Those standards and OMB Circular A-133 require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about the University's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of the University's compliance.

Opinion on Each Major Federal Program

In our opinion, the University complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2014.



Report on Internal Control Over Compliance

Management of the University is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered the University's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with OMB Circular A-133, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of the University's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of OMB Circular A-133. Accordingly, this report is not suitable for any other purpose.



December 10, 2014

Schedule of Findings and Questioned Costs

Year ended June 30, 2014

(1) Summary of Auditors' Results Financial Statements Unmodified Type of auditors' report issued: Internal control over financial reporting: Material weakness(es) identified? yes no Significant deficiency(s) identified that are not considered to be material weakness(es)? yes none reported X Noncompliance material to the financial statements noted? yes no Federal Awards Internal control over major programs: Material weakness(es) identified? yes no Significant deficiency(s) identified that are not considered to be material weaknesses? yes none reported Type of auditors' report issued on compliance for major programs: Unmodified Any audit findings that are required to be reported in accordance with section 510(a) of OMB Circular A-133? yes no Identification of Major Programs **CFDA** numbers Name of federal program/cluster Research and Development Cluster Various Student Financial Assistance Programs Cluster Various Dollar threshold used to distinguish between type A and type B programs: \$3,000,000

Auditee qualified as low risk auditee?

53 (Continued)

yes

no

Schedule of Findings and Questioned Costs
Year ended June 30, 2014

(2)	Findings Relating to the Financial Statements Reported in Accordance with <i>Government Auditing Standards</i>
	None.
(3)	Findings and Questioned Costs Relating to Federal Awards
	None.